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ABSTRACT

Maternal smoke exposure produces long-term adverse cognitive and behavioral
outcomes in offspring, including an increased likelihood of attention problems (e.g.,
attention deficit hyperactivity disorder; ADHD) and drug abuse. Preclinical research
shows that gestational exposure to nicotine, the primary psychoactive compound in
tobacco smoke, influences the neurodevelopment of attention and reward neuronal
circuits. This study investigated hypotheses about five brain regions, to determine if
prenatal nicotine (PN) exposure altered expression of nicotinic acetylcholine receptors
(nAChRs). A low dose, intravenous nicotine (IV) exposure method was used to
administer nicotine (0.05 mg/kg/injection) or saline, 3x/day on gestational days 8–21
(Treatment). Brain tissue was collected from both male and female offspring (Sex), on
postnatal days (PND) 10 and 35 (Age). Autoradiography quantified [125I]-Epibatidine,
[125I]α-Bungarotoxin, [125I]α-Conotoxin MII binding, to measure putative α4β2, α7, and
α6-containg nAChR subunit expression levels. It was hypothesized that α4β2, α7, and α6subunit-containing nAChRs in the Ventral Tegmental Area (VTA), Nucleus Accumbens
Core (NAc), prefrontal cortex (PFC), Pendunculopontine Tegmental Nucleus (PPTg), and
Hippocampus, would have significantly different expression levels between PN and
prenatal saline (PS) groups (Treatment). Males were expected to have higher levels of
nAChR expression across regions, and tissue from older (PND35; adolescent) subjects
was hypothesized to also have higher levels of nAChR expression, compared to neonates
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(PND10). Following autoradiography, receptor expression levels were analyzed with the
MicroBrightField software Densita, measuring receptor density as Luminance value, (a
lower Luminance value indicates greater density of receptors). A total of 10 rodent dams
contributed four offspring each (n=40), and the obtained Luminance values underwent
preliminary statistical screening, to determine if variance analyses should proceed with
Luminance as a Random Effect variable. If Litter did not have a significant effect
(conservative p>0.250), a between-subjects Analysis of Variance (ANOVA) was used; if
Litter had a significant effect on the shape of Luminance distribution (conservative
p<0.250), statistical analyses continued with Litter as a Random Effect in a Mixed
Models Linear (MML) analysis. Post-hoc analyses determined the retrospective power of
each observed significant effect, based on sample size and parameter estimates derived
from either ANOVA or MML. Statistically significant, sufficiently powered, main effects
of Treatment were found for α4β2 nAChR expression levels in the VTA and NAcc, but
no Treatment effect was found in the PPTg. As hypothesized, α7 nAChRs expression
levels were lower for PN rats; the effect was only seen in the NAcc, with no significant
Treatment effect found in the VTA or PFC. In the Hippocampus, Treatment was a
significant main effect, but the PN group expressed more α7 nAChRs than the PS group.
A statistically significant, sufficiently powered, main effect of Sex was found only in the
PFC; as hypothesized, Males expressed greater density of α4β2 nAChRs. Statistically
significant, sufficiently powered, main effects of Age were found for α4β2 nAChR
expression in the PFC and PPTg; in the PFC, the effect was opposite: older rats expressed
fewer α4β2 nAChRs. No age differences were found in the VTA or NAcc. For n α7
nAChRs, Age had a significant main effect in the Hippocampus, with adolescents
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expressing lower density of receptors, compared to neonates. No statistically significant,
sufficiently powered effects for α6-containing nAChRs for Treatment, Sex, or Age were
found. In addition to the five hypothesized regions, 12 more brain areas were analyzed
for α4β2, α7, and α6-subunit containing nAChR expression levels. Those results are
presented in tandem with the hypothesized findings in the Results section of this report.
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CHAPTER I
INTRODUCTION
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Maternal smoking during pregnancy: Clinical and Epidemiological Findings
Mothers who smoke cigarettes while pregnant increase the risk of health

complications for themselves and their offspring. Among pregnant American women, the
most recent reports indicate that 15.4% continue to smoke while pregnant (SAMHSA,
2014). Maternal smoking during pregnancy is correlated with several adverse outcomes
in offspring, including increased behavioral problems, cognitive impairments, and
substance use. Tobacco smoke is a neuroteratogen, and offspring of mothers who smoke
while pregnant may exhibit any number of a constellation of problematic effects.
The physical phenotype of exposure to maternal smoking during gestation can
include low birth weight (Delpisheh et al., 2006; Dunn et al., 1976; Ernst et al., 2009;
Fenercioglu et al., 2009; Kramer et al., 1990), as a result of restricted intrauterine growth
(Horta et al., 1997; Kramer, 1987; Nordentoft et al., 1996; Quinton et al., 2008). These
newborns are more likely to be born prematurely (Cooke, 1998; Cooperstock et al.,
2000), and have a higher risk of sudden infant death syndrome (Burguet et al., 2004;
Fleming & Blair, 2007; Haglund & Cnattingius, 1990).
Neonates subjected to maternal tobacco smoke during gestation have significantly
decreased head circumference, reductions of brain volume in some prefrontal cortical
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areas, and anisotropic distribution of white matter in areas responsible for attention
processing (DiFranza et al., 2004; Cornelius & Day, 2009; Ernst et al., 2009; Fenercioglu
et al., 2009). These early life biological challenges may foreshadow a myriad of
behavioral and cognitive effects following tobacco smoke exposure during gestation.

1.

Maternal smoking during pregnancy: Clinical and Epidemiological Findings

1.1 Cognitive and behavioral outcomes

Problems with attention and behavior/conduct are some of the most common
maladaptive developmental trajectories following maternal smoking during pregnancy.
A dose-dependent relationship between amount of maternal cigarettes smoked per day
during pregnancy, and incidence of conduct disorder, has been reported among PCSE
(prenatal cigarette smoke exposed) offspring. PCSE children exposed to ≥20 cigarettes
daily are most likely to display conduct disorder (Fergusson et al., 1993).
When problematic child behaviors germane to the clinical “conduct disorder”
diagnosis are assessed, these individual actions fall under the umbrella term
“externalizing behaviors.” These component aggressive and antisocial behaviors include
fighting, screaming a lot, destroying possessions, arguing, lying, and throwing temper
tantrums (Achenback & Edelbrock, 1981).
PCSE children whose mothers smoked ≥20 cigarettes daily were significantly
more likely to exhibit the maximum amount of externalizing behaviors, compared to
PCSE offspring whose mothers smoked between 1-9 daily cigarettes during pregnancy
(Williams et al., 1998). This population also shows long-term increases in delinquency,

2

behavior problems, impulsivity, and aggression (Fried et al., 1998; 2003; Brennan et al.,
1999, 2002; Weissman et al., 1999; DiFranza et al., 2004; Button et al., 2007; Cornelius
& Day, 2009).
Clinical reports of the neurocognitive teratogenicity of PCSE show that soon after
birth, abnormal emotional reactivity becomes evident, and is consequent to PCSE. PCSE
neonates are less able to self-regulate, are more distressed by novelty, and react slower
than non-PCSE neonates (Martin et al., 2006). As infants develop, additional dimensions
of dysfunction promulgated by PSCE emerge. Heavy smoking of ≥20 daily cigarettes is
predictive of reduced offspring intelligence at ages 4 and 7, as well as poor academic
performance at age 7 (Gilman et al., 2008; Polańska et al., 2015).
At six months, infants show deficits in focused attention, information processing,
and greater distractibility (Fenercioglu et al., 2009), and these early deficiencies are
followed by childhood increases in hyperactivity and inattention (Langley et al., 2005;
Jacobson et al., 2007; Cornelius & Day, 2009), as well as a three-fold increase in
likelihood of a clinical diagnosis of ADHD (Linnet et al., 2003; Thapar et al., 2003;
Button et al., 2007; Yoshimasu et al., 2009; Kovess et al., 2015). Academically, this
population performs worse on intelligence tests and is slower to learn language, reading,
and mathematics than non-PCSE children (DiFranza et al., 2004).
Therapeutic countermeasures are targeted for children and adolescents, but PCSE
exposed individuals face consequences for decades. One prospective longitudinal study
(Brennen et al., 1999) found that PCSE can predict adult male criminal behavior, and
has a significant positive relationship with lifetime criminal activity. This finding among
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adult males supports an extension of those atypical behaviors (seen in childhood and
adolescence) including conduct disorder, impulse control, and aggression.

1.2 Drug use and obesity

Recent research indicates that at least one dimension of motivation is appreciably
altered among PSCE children. Wiebe and colleagues (2015) obtained self-report
measures of smoking behavior and cotinine levels from mothers at 14 and 28 weeks of
pregnancy. Cotinine is a metabolite and biomarker for tobacco smoke exposure–the word
itself is an anagram for ‘nicotine’. At three years of age, PCSE offspring were assessed
for self-regulation. Participants were tested on cognitive and motivational self-regulation
tasks; each task measured the ability to hold information in mind while inhibiting a prepotent response behavior.
For example, one test required children to perform a go/no-go task. Each child sat
at a computer, and when the image of a fish appeared on the screen, they had to “catch
it,” by pressing a button within 1500ms. When a shark appeared, subjects had been
instructed to “let it go,” and refrain from pressing the button. This task is meant to
measure the cognitive construct of inhibition, which is a component of executive function
(Keeler & Robbins, 2011; Wiebe et al., 2015). The 3-year-olds also completed
assessments to determine motivational self-regulation.
In one task, the “goody shelf task,” children were brought into a testing room and
seated at a table. On a nearby shelf, two tempting toys were unveiled—one a flashing

4

wand, the other a jelly bean dispenser. The children were told that the toys were only for
‘looking at,’ and not to be touched. Subjects were given three crayons and a piece of
paper to draw on, while an examiner sat in the corner of the room (Wiebe et al., 2015).
Interestingly, no significant differences were found among non-PCSE and PCSE
offspring on the cognitive self-regulation tasks.
However, there were significant differences between non-PCSE children and
PCSE children on the motivational self-regulation tasks. The children prenatally exposed
to maternal tobacco smoke performed significantly worse on the tasks measuring
motivational self-regulation. These children were less likely to refrain from touching the
toys, more likely to sustain contact with the toys after the examiner reminded them not to,
and more likely to openly defy or ignore the examiner all together, and do whatever they
wanted with the toys (Wiebe et al., 2015).
Thus, these clinical reports offer a compelling indication of the risks for
dysfunctional motivated behavior patterns following PCSE.
These behaviors are primarily driven by the brains motivational neurocircuitry,
but are notably distinct from behaviors that are cognitive per se. Keeler & Robbins
(2011) discuss how motivation is inherent within a constellation of cognitive behaviors,
including inhibitory control (measured by the “go fishing” task), decision making,
flexibility, planning, long-term and working memory, attention, and perception. Keeler
& Robbins (2011) ascribe that the processes deemed “cognitive,” are essentially ways of
manipulating information in the mind, designed to detect sensory input and produce
motor output. All of these cognitive processes are couched within, and influenced by,
the organism’s motivational state (Keeler & Robbins, 2011).
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The findings by Wiebe et al. (2015) indicate that PCSE toddlers perform
differently on tasks measuring inhibitory control and motivation for hedonic reward
(flashing toy, candy in a dispenser). These findings concur with further evidence that
PCSE can influence motivation for high-fat, sugary foods in children.
Offspring exposed to tobacco smoke during pregnancy are more likely to be
clinically overweight at age 7, and PCSE children are significantly more likely to be
obese (Al Mamun et al., 2006; Jaddoe et al., 2008; Møller et al., 2014; Power & Jefferis,
2002). PCSE is significantly more likely to predict obesity than paternal smoking,
household smoking, or postnatal environmental tobacco smoke exposure. The motivated
behaviors of seeking out and obtaining natural rewards (e.g., high-fat, high-sugar foods)
engage the same neurocircuitry as behaviors involved in obtaining drug rewards and
reinforcers (Berridge & Robinson, 1998; Tomasi et al., 2015; Volkow et al., 2011).
Later in development, PCSE individuals have an increased likelihood of
substance abuse generally, (Brennan et al., 2002; Ellis et al., 2012; Goldschmidt et al.,
2012; Weissman et al., 1999); including tobacco use (Cornelius et al., 2000; Buka et al.,
2003). Cornelius and Day (2009) found that 10-year-olds with a history of PCSE are 5
times more likely to experiment with tobacco; in this study, the tendency of PCSE
offspring to smoke also continued throughout the lifespan.
At 14 years of age, PSCE offspring smoke significantly more cigarettes than nonPCSE offspring (Cornelius et al., 2000), and are twice as likely to smoke throughout
adolescence (Kandel et al., 1994; Button et al., 2007). In adulthood, PCSE exposed
individuals are classified as clinically nicotine dependent more often than non-PCSE
adults (Fergusson et al., 1998; Buka et al., 2003).
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According to Goldschmidt et al., (2012), exposure to tobacco smoke during
gestation is significantly positively related to an increased likelihood of early alcohol use
(initiation <16 years of age), with 63% of PCSE adolescents initiating alcohol use early,
compared to 45% non-PCSE. The PCSE adolescents also initiated marijuana use earlier,
and this clinical report indicates that 56% of PCSE adolescents initiated tobacco
smoking early in adolescence, compared to 43% non-PCSE.
Overall, there is a significant positive relationship between amount of cigarettes
smoked by mothers during the first trimester, and early initiation of multiple substance
usage, (including tobacco, alcohol and marijuana) in adolescence (Goldschmidt et al.,
2012). The odds of an adolescent with first trimester PCSE engaging in multiple
substance use (polysubstance use) are nearly twice as high as non-PCSE adolescents.
Environmental and genetic factors don't contribute to maternal smoking and drugseeking behavior(s) in the Goldschmidt study, and when treated as covariates, the
relationship between PCSE and drug-seeking remains statistically strong.

2.

Nicotine acts as a neuroteratogen

2.1 Nicotine

Clinical reports provide evidence for the teratogenicity of tobacco smoke.
Smoking tobacco exposes the individual, and parenthetically the fetal offspring, to 4000
disparate constituents (Rodgman & Perfetti, 2013). Existing data concedes that several
toxic compounds, (e.g., monoamine oxidase inhibitors, carbon monoxide, nitric oxide)
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contribute to adverse developmental outcomes following PCSE (Franke et al., 2007;
Mactutus & Fetchner 1984, 1985).
However, when studied alone, nicotine is a well-known neurotertatogen, with a
complex and profound influence in the developing brain (Dwyer et al., 2009; Heath &
Piccioto 2009; Roy et al., 1998; Slotkin 1998). Nicotine is the primary psychoactive
compound in cigarettes that maintains tobacco smoking addiction in humans (Benowitz
2009; Collins 1990). Changes in the trajectory of development for multiple neural
systems is associated with prenatal nicotine exposure (Dwyer et al., 2008; Harrod et al.,
2011; Kane et al., 2004; Muneoka et al., 1999; Morgan et al., 2013).
Smoking a cigarette causes plasma nicotine levels to peak rapidly, due to the
pharmacokinetic profile of inhaled tobacco smoke. About 1-2 mg of nicotine is absorbed
systemically during smoking (Benowitz & Jacob, 1984). The surface of the lungs has a
large alveolar blanket (Benowitz, 1990), which allows rapid distribution from the lungs to
blood, with nicotine reaching the brain in about 7-10 seconds (NIDA Research Report,
1998).
The rapid rise of nicotine in the brain is temporary, and the ‘bolus’ of nicotine is
an effective reinforcer for the smoker (Russell & Feyerabend, 1978). Because nicotine is
highly lipophilic, it easily absorbs in mucosa, the gastrointestinal tract, and readily
crosses the fetal placenta, where it enters fetal serum and permeates the blood brain
barrier (Luck et al., 1985). During maternal smoking, nicotine acts as an exogenous
ligand for neuronal nicotinic acetylcholine receptors (nAChRs) in the developing fetal
brain. Nicotine is an agonist and can bind nAChRs with a range of affinities, depending
on receptor stoichiometry.
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2.2 Acetylcholine (ACh)

Acetylcholine (ACh) is the endogenous neurotransmitter for nAChRs. ACh is
synthesized from choline, found in circulation. The first step in ACh synthesis is ratelimiting, when choline is taken into the presynaptic cell by a high affinity choline uptake
transporter (CHT) system, where choline acetyltransferase (ChAT) catalyzes the
synthesis of ACh (Wu et al., 2015).
ACh is loaded into vesicles by the vesicular ACh transporter (VAChT), and
released from the presynaptic neuron. In the synaptic cleft, acetylcholinesterase (AChE)
hydrolyzes ACh back into choline and acetate. About 50% of hydrolysis-derived choline
is reacquired for ACh production (Amenta & Tayebati, 2008).
Ionic flow across the cell membrane is a function of ACh release and nAChR
binding. An influx of cations through channel pores increases cell excitability by
depolarizing the membrane, with Ca2+ in particular triggering a substantial series of
intracellular signaling cascades (Colombo et al., 2013). nAChRs are found in abundance
throughout the CNS, and belong to a cys-loop superfamily of ligand-gated ion channels
that includes GABA, glycine, and 5-HT3 receptors (Betz, 1990).

2.2.1 nAChRs

Two forms of AChRs exist in mammalian species, nicotinic and muscarinic
(mAChR) AChRs. nAChRs are widely expressed in the CNS where they qualitatively, if
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not quantitatively, modulate neurotransmitter release via actions in pre-, post-, and
extrasynaptic membranes (Amenta & Tayebati, 2008; Vizi et al., 2004).
Symmetrically pentameric, nAChRs are cation selective (including Na+, K+, and
Ca2+) and each has five subunits characterized by their composition around a core ionconducting pore (Fucile, 2004; Wu et al., 2015). A single nAChR subunit is typically 600
amino acids long (Hogg et al., 2003). There are 12 putative nAChR subunits, (α2 -α10
with the α8 subunit primarily functional in avian species) and (β2-β4), and receptors exist
with some plasticity in convertible states, whose constitution is primarily driven by the
binding of agonists and antagonists (Role & Berg, 1996). Stoichiometry regulates the
neurophysiological characteristics of nAChRs, with each receptor either homomeric (α7)5
or heteromeric, such as α4β2.
The heteromeric nAChRs have two ACh binding sites (per pentameter), found
where certain subunits come together—where an α2, α3, α4 or α6 subunit meets a β2 or
β4 subunit. The most common nAChR conformations are (α4)2(β2)3 and (α4)3(β2)2
(Lindstrom, 2000). In contrast, α7 homomeric receptors have five identical ligand
binding sites at the interface between each subunit (Gotti et al., 2009). Nicotine is
powerful as an nAChR agonist, and acts to promote binding of nAChRs that have a high
affinity for nicotine, particularly the sensitive α4β2 nAChR (Kuryatov et al., 2005).
Chronic nicotine acts to desensitize nAChRs. Desensitization is a standard term
describing the loss of receptor activity after sustained stimulation (Ochoa et al., 1989).
nAChRs don’t naturally desensitize to ACh, because endogenous ACh normally doesn’t
reach high enough concentrations, and the amount of time ACh interacts with nAChRs to
cause activation is negligible (nanoseconds).
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However, chronic exposure to nicotine drives receptors into desensitized, nonconducting conformational states (Lukas, 1991; Marks et al., 1993; Peng et al., 1994).
Smoking tobacco leads to the prolonged temporal exposure of receptors to nicotine, and
and increased concentration of nicotine in the brain.
During tobacco dependence, chronic exposure causes protracted nAChR
desensitization, and nAChRs in the brains of smokers are said to depress into “deeply
desensitized states,” and these states of deep desensitization cause an upregulation in
nAChR receptor number (Dani & Heinemann, 1996; Fenster et al., 1999).
Following this, nicotine can induce upregulation and actually promote
intracellular assembly of high-affinity nAChRs. Individual α and β subunits exist in a
neuron’s cellular endoplasmic reticulum (ER), and during chronic nicotine exposure, an
upregulation of high-affinity membrane nAChRs reflects nicotine-driven assembly of
nAChRs from pools of subunits in the ER. Moreover, when comparing the effects of
nicotine, to prolonged ACh exposure, (achieved by incubating cells with 300µM of ACh
and with an AChE inhibitor) only during chronic nicotine do high-affinity α4β2 nAChRs
preferentially assemble and upregulate from the ER (Kuryatov et al., 2005).
nAChRs are distributed widely within the CNS, and regulate a constellation of
developmental and neurocognitive functions. In the earliest stages of life, these receptors
and their binding ligands modulate cell proliferation, survival, differentiation, gene
expression, synapse formation and maturation, axonal pathfinding, and neurotransmitter
release (Dwyer et al., 2009). The α6 and α7 subunit-containing nAChRs, along with the
α4β2 nAChRs, peak within the first three weeks of birth, and then begin to decrease in
density, with expression levels plateauing and stabilizing throughout adulthood and aging

11

(Azam et al., 2002; Hellstrom-Lindahl et al., 1998; Hellstrom-Lindahl & Court, 2000).

2.2.2 ACh during neurodevelopment

Acetylcholine has a fundamental role in the development of fetal brain tissue.
ACh is active in the fetus as early as the gastrulation phase, beginning gestational day
(GD) 6, as evidenced by the appearance of the synthesis enzyme ChAT as well as the
hydrolyzing enzyme AChE, which appears when ACh begins guiding morphogenic cell
organization (Hohmann, 2003; Kassam et al., 2008; Dwyer et al., 2009).
In the spinal cord and brain stem, nAChRs appear by GD 11, and can be
desensitized by chronic exogenous nicotine in the brain. After initial gestational nAChR
innervation, these receptors continue to aggregate all over the brain, regionally and
transiently (indicating certain “critical periods” in typical brain development, when
nAChRs appear, along with excitatory ACh, to stimulate and provide guidance for
extensive heterogeneous brain region development). nAChRs appear in multiple cortical
layers, where ACh regulates neurotransmission and information flow, influencing
neurons of various classes (Xiang et al., 1998).
Prenatal nAChRs are flexible and multifunctional, with responsibilities including
the formation of rudimentary sensory and neural circuitry. The appearance of nicotine as
exogenous agonist during gestation can have wide-ranging effects. For example, the α7
homomeric nAChR induces CA2+ entry immediately after formation of the
neuroepithelium, making nAChRs responsible for very early neuronal pathfinding and
survival. During prenatal development, stimulating the α7 receptor causes neurite
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retraction (Pugh & Berg, 1994; Small et al., 1995); when α7 is antagonized, neurites
extend (Lipton et al., 1988). In the normally developing brain, bursts of ACh procure
symmetrical, balanced gradients to guide the direction of forthcoming neurite growth
(Zheng et al., 1994).
The α7 subunit is also responsible for orchestrating the processes of apoptosis,
cell projection, and maintaining the balance of cell production and recycling (Opanashuk
et al., 2001; Hauser et al., 2003). The α6 nAChR mRNA appears at GD 15, and regulates
the development of growing DA neurons (Azam et al., 2007). Introducing a high-affinity
ligand such as nicotine during these critical periods changes brain growth during critical
phases.
Brain formation relies on cell differentiation from stem cell precursors, migration
of immature neurons from the embryo, outgrowth of axonal and dendritic processes; and,
ultimately, axonal pruning and cellular apoptosis—all of which are managed by ACh via
the nAChRs.
ACh is influential as a trophic factor, promoting mitosis in fetal neurons and later
prompting cells to undergo differentiation for specificity (Slotkin et al., 2004). Overall,
the cholinergic system plays a major role in corticoceptal cytoarchitectural development:
neurite growth, controlling cell number, apoptosis, differentiation, and pruning.

3. Animal models of maternal smoking during gestation

Several decades of clinical research reports provide a rich behavioral composite
of the long-term consequences of PCSE. Given the >4000 constituents in tobacco smoke,
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animal research provides techniques to isolate the precise behavioral- andneuroteratogenic effects of nicotine alone (Slotkin, 1998).
Although not an exact facsimile of the human CNS, there is remarkable
phylogenetic conservation in the rat CNS (Keeler & Robbins, 2011). Animal models of
prenatal drug exposure allow systemic and controlled drug delivery. These models are
based on three routes of administration: subcutaneous, oral, and intravenous injection.
Each has a unique pharmacokinetic profile.

3.1 Subcutaneous route of administration

Historically, the first studies of PN exposure used subcutaneous (SC) injections to
deliver nicotine throughout gestation, and attempted to equate a range of the total amount
of nicotine absorbed by humans during daily smoking (1-5 mg/kg/day), (Becker et al.,
1968; Hammer et al., 1981; Hudson & Timiras, 1972). This method resulted in decreased
maternal weight gain, pup birth weight, maternal food intake, and an increased duration
of gestation (Becker and Martin, 1971; Martin and Becker, 1971). Additionally, this dose
range of SC nicotine reduces uterine blood flow and intrauterine oxygen availability
(Hammer et al., 1981). The reduction of blood flow and oxygen causes transient ischemic
fetal hypoxia following each injection.
The subcutaneously –implanted osmotic minipump (OMP) is the most often cited
route of PN administration. The OMP is placed in a subcutaneous pouch and releases
nicotine into the subcutaneous compartment to be slowly absorbed into the bloodstream
and distributed to the dam and fetuses.
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The OMP represents a steady-state model of exposure; nicotine is slowly,
continuously released, with most OMPs expiring after 28 days (Slotkin et al., 1987b;
Levin et al., 2006). A steady titer of nicotine is released into the dam’s body and fetuses,
and early research with this device typically included doses meant to mimic heavy
smoking (6-9mg/kg/day), which is higher than corresponding human levels of plasma
nicotine produced by smoking. For example, a human female has to smoke 360 cigarettes
per day to achieve the blood plasma levels produced by a 6mg/kg/day OMP (Mactutus,
1989), although more contemporary experiments use 2-3mg/kg/day, which represents
levels obtained in moderate smokers (Dwyer et al., 2008).
Uterine and placental blood flow are reduced by up to 40% with the OMP
(Birnbaum et al., 1994) but the steady-state dosing doesn’t imitate the spike of nicotine
bolus in the brain and blood plasma experienced by smokers.
One advantage of the minipump is the elimination of daily stress cause by
handling and injections. However, as the devices have standard expiration dates, they
must be surgically implanted either immediately prior or following confirmation of
pregnancy, which carries the risk of stressing the dam (Mactutus, 1989).

3.2 Oral route of administration

Nicotine dissolves in dams’ drinking water via the oral route of administration.
Subjects (1) may have access to only nicotine-dosed drinking water, (Pauly et al., 2004;
Peters & Tang, 1982; Schneider et al., 2010), or (2) access to both nicotine water and
non-nicotine water during pregnancy (Paz et al., 2007; Thompson et al., 2011). Oral
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nicotine is subject to first-pass metabolism, as it slowly passes through hepatic portal
circulation, reducing the amount of nicotine absorbed into the blood. Seventy percent of
nicotine taken orally is metabolized by the liver before reaching the brain (US DHHS,
1988). These studies typically require a higher dose to reach plasma levels similar to
smoking (Pauly et al., 2004; Sparks & Pauly, 1999).
Oral administration has an advantage of being non-stressful to the pregnant dam.
Rats are typically neophobic and don’t readily consume nicotine water; introducing as
little as 0.2% nicotine into drinking water can reduce overall water consumption by 50%
(Murrin et al., 1987). The oral method does not provide ‘spikes’ of nicotine in the blood
and brain seen in smokers. This “spike” and concurrent neurotransmission underlies
nicotine’s addictive properties (Mactutus et al., 1994; Russell & Feyerabend, 1978).
However, as rats drink water periodically throughout the day, the oral method can
provide an ongoing dosing regimen, somewhat similar to smoking patterns.

3.3 Intravenous (IV) route of administration

The IV route of nicotine administration closely mimics the pharmacokinetic
profile of blood nicotine concentrations via tobacco smoke inhalation (Benowitz et al.,
2009; Booze et al., 1999a). The “puff” of inhaled tobacco smoke leads to a rapid peak
level of nicotine the brain (Mactutus et al., 1994; Russell & Feyerabend, 1978). Similar to
smoke inhalation, an IV injection causes rapid absorption and distribution of nicotine
(Booze et al., 1999a).
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The IV route offers 100% bioavailability into the arterial circulation (Benowitz et
al., 2009; Booze et al., 1999a; Mactutus et al., 1994). In 1993, Henningfield and
colleagues captured both arterial and venous plasma nicotine levels from human male
habitual smokers, directly after the subjects smoked one cigarette (following several
hours’ abstinence). Capillary gas chromatography analysis of frequent samples collected
the first few minutes after smoking revealed arterial nicotine in the plasma is dramatically
higher than venous levels, with highest levels recorded between 5-6 minutes.
Arterial samples are precise comparisons of drug levels in the brain, because of
the rapid temporal equilibration of nicotine concentration between the brain and arterial
blood following inhalation (Henningfield et al., 1993). The inhalation and intravenous
routes are pharmacokinetically extremely similar. Although the two send drug to the
brain via slightly different anatomical paths, the total bioavailability of IV drugs after
injection imitates the rapid distribution half-life of inhalation, and effectively removes
any variability introduced with the kinetic component of absorption (Booze et al., 1999).
An early preclinical study by Adir et al., (1976) analyzed aortic blood after IV
administration of radioligand-labeled nicotine via the penis vein in the rat. Nicotine in
blood samples from an indwelling abdominal aortic cannula after injection revealed the
distribution half-life (highest drug levels seen 5-6 minutes following injection) of IV
nicotine to mirror human levels after tobacco inhalation (Adir et al., 1976; Henningfield
et al., 1993).
Booze et al., (1999) demonstrated that using an indwelling jugular catheter first
used in Mactutus et al., (1994), to administer IV nicotine in rats, produces an extremely
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close match to human arterial nicotine plasma levels following inhalation, with an
average 5 minute distribution half-life, and 50 minute elimination half-life.
Furthermore, his technique allows multiple daily injections, capable of modeling
the repeated spikes of the nicotine bolus in the brain produced by tobacco smoking
(Mactutus, 1989; LeSage et al., 2006). The earliest preclinical studies of IV PN reported
use of an indwelling cannula. A tether connected the cannula to an automated pump, to
deliver 0.03 mg/kg/injection every 14 minutes, for 16 hours a day, for a total of 2.0
mg/kg/day (Keyler et al., 2005, LeSage et al., 2006).
Using a free-hand injection IV model allows the researcher to administer nicotine
concentrations to mimic dosing regimens seen in drug dependence, including nicotine
self-administration (Donny et al., 1995; Donny et al., 1998). The IV model in the current
set of experiments delivers 0.05 mg/kg/injection of nicotine, three times per day. This
dosing regimen maintains nicotine self-administration in rats (e.g., 0.03 – 0.06
mg/kg/infusion; Donny et al., 1995; Donny et al., 1998; Corrigall & Coen, 1989), and
produces sensitization of brain regions responsible for reinforcement learning and reward
seeking behavior (Booze et al., 1999a; Harrod et al., 2007; Harrod et al., 2004). The
elimination half-life (T1/2β) of IV nicotine via catheter is about 50 minutes (Booze et al.,
1999).
In the proposed set of experiments, the dose of 0.05mg/kg were given at 1000,
1300, and 1600. From 1000-1300, and from 1300-1600, 3.5 elimination half-lives will
pass, and each dam will have trace amounts of nicotine in their blood plasma. At the time
of the second injection, 9.375% of the drug concentration from the first dose (0.0046875
mg/kg) was bioavailable in blood plasma, resulting in an incrementally additive effect of
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the first and second injections. The third and final nicotine dose will add 0.05mg/kg to
0.0051269 mg/kg, already present in the dam’s blood plasma. For a 12-hour profile of
nicotine elimination in the proposed set of experiments, see Table 1.
Animal models of PN exposure are advantageous for studies of
neuropharmacological alterations that may support maladaptive neurobehavioral
outcomes following maternal smoking.

4. Neurodevelopmental effects of prenatal nicotine: Preclinical Findings

4.1 The Cholinergic System: changes in brain growth and nAChRs

In PN rats, gross DNA levels are reduced by 10-20% in the brain stem, midbrain,
cerebral cortex, and cerebellum. One nucleus is present in each brain cell, so decreased
DNA directly reflects fewer numbers of cells in the brain (Slotkin et al., 1987b). Levels
of the enzyme ornithine decarboxylase (ODC) are significantly higher among postnatal
PN rats; ODC controls cell replication and differentiation. Higher ODC levels reflect a
premature switch from replication to differentiation (Slotkin et al, 1987b).
PN interferes with the ability of ACh and nAChRs to properly control neurite
growth (Lauder & Schambra, 1999). For example, α7 nAChRs both inhibit and stimulate
neurites—and introducing PN wreaks havoc on these tightly orchestrated developmental
milestones, and can also highjack nAChRs meant to guide neurites during pathfinding to
their proper brain regions.
Significantly lower DNA levels for PN rats two weeks after birth reflects the
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interruption of another critical α7 mediated developmental event—apoptotic programmed
cell death (Slotkin et al., 1987b; 1999). The α7 nAChR facilitates timed cell death of
motoneurons in the spinal cord (Renshaw et al., 1993), and is a known agent of
hippocampal and cortical pruning via direct Ca2+ influx (Orr-Urteger et al., 2000).
Nicotinic receptors are phasic agents of programmed apoptosis, as a necessary step in
healthy brain growth.
However, apoptosis is endogenously accomplished by ACh, and the introduction
of exogenous nicotine causes premature cell death, and an increase in apoptosis beyond
normal programmed cell death (Slotkin et al., 1987b; Berger et al., 1998). The
introduction of a gain-of-function α7 nAChR mutant causes dramatically increased
apoptosis and death in the first post-natal day (Orr-Urteger et al., 2000).
PN is also capable of transiently upregulating nAChRs in the developing nervous
system (Broide et al., 1995; Duncan et al., 2015; van de Camp & Collins, 1994; Tizabi et
al., 1997). Phasic nAChRs express subunits which often change confirmation during
critical phases of brain maturation (Abreu-Villaça et al., 2010; Zahalka et al., 1993).
Nicotine has different binding affinities for each nAChR confirmation, and because of the
(1) variability of receptor confirmations, (2) nicotine’s versatile affinities for nAChRs,
and (3) the transient upregulation of receptors during brain development, PN causes
complex and far-reaching aberrations of development and neurotoxicity during the
earliest stages of growth.
PN perturbs synaptogenesis and synaptic function of the nicotinic receptor;
nAChRs experience long-term changes in synaptic morphology when challenged with PN
exposure. A seminal set of experiments by Zahalka et al., (1993) showed that PN-
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exposed animals had significantly higher numbers of ACh binding sites on nAChRs, and
upregulated nAChRs across brain regions.
Zahalka et al., (1993) also reported higher ChAT activity, reflecting prolonged
spikes in axonal outgrowth and synaptic proliferation. This indicates the synthesis of both
ACh and nAChRs are symbiotically responding to PN exposure, both working to adjust
to the unnatural influx of nAChR agonist. PN exposure during vulnerable periods of
ontogenesis sets the brain upon a trajectory of structural malformation, and maladaptive
functioning for the lifespan.
The arrival of PN during gestation affects the brain during critical periods when
the content and connections for areas that drive the behaviors of attention and motivation
are developing, giving PN an especially insidious role in abnormal lifespan development
(Slotkin 1987a; Navarro et al., 1987).

4.1.1 The Basal Forebrain Cholinergic System:

Neonatal rodents experience the human equivalent of the “third trimester” of
gestation during the first week and a half of life—during this stage, burst firing of ACh
guides cortical growth. While ACh is prolific in the developing brain, the Basal Forebrain
Cholinergic System is the principle source for extrinsic ACh fibers in the neocortex
throughout the lifespan. The BFCS is structurally and functionally complex, producing
widespread ACh fibers throughout the brain.
Prenatally, the presence of ChAT and AChE indicates that cholinergic projections
appear very early on. Enzymatic evidence of ACh first appears in the forebrain by GD 14
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(Abreu-Villaça et al., 2010; Semba, 1992). BFCS innervation of the neocortex coincides
temporally with cortical synapse formation, illustrating the importance of ACh for
inducting cortical plasticity (Dwyer, 2009; Hohmann, 2003).
BFCS ACh projections regulate neural activity underlying processes of attention,
memory, and motivation, directing a litany of clinically relevant behaviors. There is
variability in the neuroanatomical literature defining precise anatomical boundaries of the
BFCS. The structures typically named as part of the BFCS include, but are not limited to,
the ventral pallidum, globus pallidus, substantia innominata, septum, diagonal band of
Broca, and extended amygdala (Mesulam et al., 1983; Zaborsky et al., 2012).
These areas can be further subdivided, to reveal a complex mosaic of ascending
acetylcholinergic nuclei. These components project to brain regions important for
learning, memory, and motivation. Cholinergic neurons have widespread cerebral cortex
projections, and the BFCS provides the main cholinergic drive into the PFC, the
hippocampus, and Nacc (Mesulam et al., 1983).

4.1.1.1 The Prefrontal Cortex: attention, and the role of nAChRs
The BFCS is a hub of neural outputs directing attention processes and behaviors.
About 19% of cholinergic neurons originating in the BFCS project axons to the PFC.
These ‘corticoceptal’ cells project from the substantia innominata/ventral pallidum and
nucleus basalis magnocellularis to the PFC (termed ‘Ch4’ cell bodies; Mesulam et al.,
1983), where nAChRs mediate attentional processes and executive function by
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moderating glutamatergic input into pyramidal cells (McCormick, 1993; Methrate &
Ashe, 1993).
ACh acts via the α4β2 nAChR to regulate multiple attentional processes,
including cue detection, divided attention, and sustained attention. α4β2 nAChRs
manage the responses of pyramidal cells to glutamatergic influence (Dalley et al., 2004;
Parikh et al., 2008; 2010; Howe et al., 2010; Sarter and Bruno, 1999). The PFC also
regulates behavior related to emotional reactivity—inhibiting inappropriate emotions,
impulses, and habits (Miller, 2000).
BFCS lesions show impairment of divided attention behavior and point to BFCSgenerated cholinergic corticopetal projections, as responsible for managing attentionprocessing resources. Turchi & Sarter (1997) report that ACh activity directs behavior to
resolve conflicting divided attention demands—in this case, a speed-accuracy tradeoff
was directed by ACh, and the task became impossible when cholinergic corticoceptal
projections were lesioned.
Both α4 and α7-subunit containing nAChRs are found in the PFC. Kassam et al.
(2008), showed that stimulation of the α4α5β2 neuron during the first postnatal month
produces pyramidal excitatory currents in the PFC. This effect is paired with evidence
that a functional loss of the β2 subunit in the first two postnatal weeks (but not later in
life) causes decreases in the ability to learn. BFCS-originating corticothalamic neurons,
shown to regulate attentional processing behaviors, are generated by α4α5β2-mediated
cholinergic excitatory input during the third trimester (Dwyer et al., 2009).
In vitro animal models of prenatal nicotine (PN) show long-term changes
attention-allocating neurochemical brain systems. The five-choice serial reaction task is a
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rodent model of attention and cognitive ability.
Adult rats born to pregnant dams who were exposed to a low dose of nicotine
(0.06 mg/ml) in drinking water, performed worse on errors of omission, worse on
accuracy, and had more variable response times (Schneider et al., 2011).

4.1.1.2 The Hippocampus, Basolateral Amygdala and Cingulate Cortex

BFCS projections termed “Ch2” emanate from medial septum and diagonal band
of Broca, to provide the main cholinergic innervation of the hippocampus (Mesulam
1983); the hippocampus is characterized as the most vital region for memory functioning
(Aggleton & Pearce 2001). Both α7 and α4β2 nAChRs are found in the hippocampus and
are active during memory processes. When selective antagonists for both the α7 and α4β2
nAChRs are infused locally into the hippocampus, memory functions and performance on
the radial arm maze is compromised (Felix & Levin, 1997; Levin et al., 2002; 2015).
During gestation, transient ACh interneurons act as ontogenetic regulators in the
hippocampus. Prenatally and during the early postnatal weeks, the hippocampus needs
nAChRs to grow in size, and to change GABA from excitatory to inhibitory before the
end of the third trimester (Lauder & Schambra, 1999; Dumas 1995). During this third
trimester—in the rat, the first ten postnatal days—hippocampal expression of both α7 and
α4β2 nAChRs peaks, followed by a decline to adult levels (Court et al., 1997).
PN exposure is a well-known agent of impaired performance on memory tasks. In
a classic study by Sorenson et al. (1991), following high-dose dam prenatal nicotine
exposure via drinking water (6.0mg/kg/day), late-adolescent PN subjects were
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significantly less capable of learning to navigate an 8-arm radial maze. Li et al., (2014)
report that rats exposed to PN (6mg/kg) via OMP had longer escape latency times in a
Morris Water Maze experiment, as well as reduced α7 nAChR protein expression levels
in the hippocampus in adulthood.
The BLA is functionally connected with the Hippocampus, as a part of
neurocircuitry underlying the emotional processing of stimuli, emotional memory and
learning, (Pidoplichko et al, 2013; Subramaniyan & Dani, 2015). Acquisition of
stimulant-seeking behavior is regulated by efferents sent from the BLA to the NAcc, and
lesions of the BLA prevent the acquisition of drug-seeking behavior (Whitelaw et al.
1996). Activation of both α7 and α4β2 nAChRs in the BLA are a function of rewardbased learning and seeking behavior.

The Cingulate Cortex has emerged in recent decades as an area integral to
the processing of reward-related stimuli. Both α7 and α4β2 nAChRs are located in the
CC, and midbrain DA burst firing is activated by stimulation of the CC, and this region is
known to be structurally altered by prenatal nicotine exposure (Zhu et al., 2012).
4.1.4 The Pedunculopontine Tegmental Nucleus: attention, drug seeking, and the role
of nAChRs

The Pedunculopontine Tegmental Nucleus (also called the Pedunculopontine
Nucleus; PPN), is considered the ‘cholinergic arm’ of the reticular activating system
(RAS) and is a moderator of arousal and waking states. The PPTg cytoarchitecture is
defined by large ‘Ch 5’ cholinergic multipolar neurons. The PPTg receives input from
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several brainstem regions relaying autonomic information, with output efferents
extending to brain areas key for both attention processes and drug abuse behavior.
The PPTg sends cholinergic projections to the BFCS in response to arousal cues.
The PPTg also sends cholinergic axons to the VTA and NAcc, where ACh innervates on
DA neurons via nAChRs, moderating DA release (Maskos 2008, 2010).
A set of experiments by Inglis et al., (2001) found that lesioning the PPTg reduces
performance on a 5-choice serial reaction time task. Accuracy and speed were both
decreased among those with PPTg lesions; the authors conclude that the role of the PPTg
in attentional processing is to affect global, rather than specific, attention processes. The
PPTg is thus part of an attention-allocating neurocircuitry, likely affecting DA neurons in
the PFC responsible for attention processes.
The PPTg is also engaged during actions involved in drug-taking behavior, and
PPTg ACh-positive neurons are activate when an animal actively seeks psychostimulants
(Urbano et al., 2015). Lesions to the PPTg result in reduced nicotine self-administration
(Picciotto & Corrigall 2002; Lanca et al., 2000).
In rats prenatally exposed to tobacco smoke, cholinergic neurons were “rendered
more excitable,” according to a study by Good et al., (2006). Following tobacco smoke
exposure during gestation, intracellular recording in adult rats showed that changes in
membrane potential and action potential threshold made these neurons more unstable.
The ACh neurons were more likely to fire, and fired more frequently (Good et al., 2006).
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4.2 The Dopaminergic Systems

In the adult rat, DA neurotransmission regulates the neural circuitries underlying
cognitive and behavioral processes, including attention and motivation (Nestler &
Carlezon, 2006). nAChRs densely innervate neurons in dopaminergic pathways,
including those that originate from the A9 (nigrostriatal) and A10 (mesocorticolimbic)
dopamine cell bodies (Anden et al., 1964; Chang, 1988). Prenatally, DA neurons of the
VTA appear around GD13, and those fibers advance onto neocortical structures by GD15
(Kalsbeek et al.,1988).
nAChRs on DA cell bodies are critical for dopaminergic neurodevelopment. For
example, mRNA for DA receptors is expressed prenatally, but doesn’t translate into
functional binding sites until nearby differentiated neurons release DA (Jung & Bennett,
1996). Activation of presynaptic nAChRs causes this widespread DA release from DA
terminals, allowing DA neurotransmitter to reach receptor mRNA (Leslie et al., 2002;
O’Leary & Leslie, 2003). Dopamine is dependent on nAChRs to develop the extensive
innervation patterns seen in the adult brain, which allow DA to be one of the most
widespread and influential neurotransmitters in the brain.

4.2.1 The Prefrontal Cortex: dopamine, nAChRs, and attention

The PFC has an extensive pattern of connectivity, putting this region in a unique
anatomical position to subserve “higher level” executive cognitive functions
(Weinberger, 1993). DA is recruited for the cognitive behavior of inhibiting prepotent
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responses (von Gaalen et al., 2006), is active during tasks of visual attention and working
memory (Chudasama & Robbins, 2004), and fires when an individual is engaged in
activities requiring divided, selective, and sustained attention (Granon et al., 2000).
Attentional processes are driven by ACh-positive projections from the BFCS to
PFC. In the PFC, ACh fibers innervate GABAergic interneurons and glutamatergic
pyramidal neurons (Parikh et al., 2010), influencing DA transmission. Both α7 and α4β2
nAChRs are localized in the PFC, with cortical α4 and β2 mRNA peaking on PND 14
and remaining high throughout adulthood (Aracri et al., 2009; Duffy et al., 2009; Shacka
et al, 1997).

4.2.2 Motivational neurocircuitry: role of nAChRs

The neurocircuitry underlying motivated behavior, including drug and reward
seeking, is known as the ‘mesocorticolimbic (MCL) dopamine system’. The MCL is
primarily composed of the VTA, the NAcc, and the PFC (Evenden & Ryan, 1988; Wise
& Rompre, 1989). DA release in this circuit is essential for motivation and reinforcement
learning (Beeler et al. 2010; Berridge 2004; Berridge & Robinson, 1998; Everitt et al.,
2008; Nicola 2007).
The α7, α4β2 and α6-subunit containing nAChRs are highly expressed in the
MCL. Excitatory cholinergic projections from the PPTg innervate DA neurons of the
A10 cell group in the VTA (Omelchenko & Sesack 2005), and all three nAChR subunits
are localized in the VTA and NAcc, where they modulate DA transmission (MameliEngvall et al., 2006; Yang et al., 2009). As part of the MCL, DA projections from the

28 27

VTA travel to the NAcc and PFC.
The α6 nAChR subunit only appears in a few midbrain structures, and the main
responsibility of this subunit is to regulate DA neurotransmission (De Biasi & Dani,
2011; Exley et al., 2008; 2011; McCallum et al., 2005; Pons et al., 2008). When DA
neurons are lesioned or rendered inactive, 87% of the detectable α6 protein disappears in
the midbrain (Salminen et al., 2004). Transgenic rats with gain-of-function α6 subunits
show enhanced dopamine release and locomotor activity (Drenan 2008; Wang et al.,
2014).
The α6 nAChR subunit is expressed in both the VTA and the NAc (Brunzell et
al., 2010; Gotti et al., 2010). When an α6 subunit antagonist is applied to the NAc shell,
DA release essentially comes to a halt, and α6 nAChRs are thought to control DA release
in the NAc (Livingstone & Wannacott, 2009; Yang et al., 2009). These subunits are also
the most sensitive to nicotine (Kurytov & Lindstrom, 2011; Salminen et al., 2004)
Prenatal nicotine can extensively affect neurochemical expression in the MCL, as
evidenced by changes in motivated behavior. Data from our laboratory shows PN rats are
more motivated to self-administer sucrose on a progressive ratio schedule (Lacy et al.,
2012), and will also self-administer a lower dose of IV methamphetamine, indicating
greater sensitivity to the rewarding effects of methamphetamine (Harrod et al., 2012).
The α4, α6, and β2 subunits are all essential for addiction to nicotine. Pons et al.,
(2008) used receptor knockout (KO) models to determine the roles of the α4, α6, β2, and
α7 subunits in nicotine addiction. KO-wild type pairs were trained to self-administer
nicotine, but those subjects who had the α4, α6, or β2 genes knocked out did not selfadminister the reinforcing dose of nicotine, compared to WT. When this trio of receptor
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subunits were re-expressed in the KO subjects, only those with re-expression in the VTA
(compared to the SN) restored responding to nicotine.
The α4, α6, and β2 nAChR subunits are all implicated in cognition, attention, and
motivation. Prenatal nicotine exposure is capable of changing expression patterns for
nAChRs throughout the CNS, and these changes can last into adulthood.

4.3 Hypotheses
The goal of this experiment is to investigate changes in nAChR expression
following prenatal exposure to low-dose IV nicotine or saline. In a semi-quantitative
manner, in vitro autoradiography will use radioligands to bind and label nAChRs for
density measurements. The autoradiography will label high-affinity α6 and α4β2
heteromeric nAChRs and of low-affinity α7 homomeric nAChRs within the CNS of the
rat, for anatomical receptor density comparisons. Previous research by Tizabi et al.,
(1997; 2000) shows that nAChR expression levels are significantly different between PN
and PS rat offspring on postnatal days 35-38.
It is predicted that (1) nAChR expression levels were significantly different
between PN and PS rats. Specifically, PN levels of α4β2 nAChR binding are expected to
be greater than PS levels in the PFC, NAc, VTA, and PPTg, similar to findings of Tizabi
et al., (1997). Expression of the α7-subunit containing nAChRs is expected to be lower in
PN animals.
Based on these findings, along with similar results from Tizabi et al., (2000), PN
levels of α7 nAChRs are expected to be significantly lower than PS binding levels in the

30 29

hippocampus and PFC.
This experiment was the first to investigate expression levels of the α6 nAChR
following PN exposure. α6 nAChRs are localized almost exclusively on midbrain DA
neurons (Yang et al., 2011), and Richardson & Tizabi (1993) found that PN-exposed
offspring express fewer DA neurons in the VTA. It is hypothesized that PN and PS
groups will have significantly different α6 expression levels, however, these differences
are expected to be a function of age (see below).
(2) nAChR levels across regions are expected to differ as a function of age. This
experiment was the first to compare neonatal (PND10) and adolescent (PND35) nAChR
expression in PN and PS offspring. Tizabi et al., (1997; 2000), found higher α4β2 levels
in the PFC, NAc, and VTA of PN rat at PND 35, but also lower α7 expression in the
hippocampus and PFC at PND 36-38.
Considering basal levels, the α6, α7 and α4β2 nAChRs first appear during the
second gestational trimester, then climb steadily to peak by PND 21, followed by a
decline to levels maintained through adulthood (Azam et al., 2007; Pugh & Berg, 1994;
Small et al., 1995; Xiang et al., 1998). It is predicted that there will be significant
differences in nAChR expression levels between age groups, as well as an interaction
between prenatal nicotine exposure and age.
Lastly, (3) it is hypothesized that nAChR expression will be different between
males and females. Tizabi et al., (1997) previously showed that PN males had
significantly higher whole-brain levels of α4β2 nAChR expression, compared to PN
females. The later Tizabi et al., (2000) report of α7 nAChR levels following PN exposure
included only male offspring. No evidence to-date addresses sex differences in α7 or α6
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nAChR expression. It is predicted that there will be significant sex differences in nAChR
expression, as well as an interaction between prenatal nicotine and sex.
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Table 1.1 Nicotine concentration metabolism from blood plasma.

^^

Time of day
(injection = 0.05mg/kg)

T1/2β
Percent of nicotine in Mg/kg of drug
(elimination plasma (since most
concentration
half-life)
recent injection)
in plasma

1000 (1st injection)

0

100%^^

0.05

1050

1

50%

0.025

1140

2

25%

0.0125

1230

3

12.5%

0.0625

1300 (2nd injection)

3.5

9.375%

0.0046875

0 (upon
injection)

100%^^

0.0046875+0.
05 (additive)=
0.0546875

1350

1

50%

0.02734375

1440

2

25%

0.01367187

1530

3

12.5%

0.00683593

1600 (3rd injection)

3.5

9.375%

0.00512695

0 (upon
injection)

100%^^

0.00512695+0
.05
(additive)=
0.05512695

1650

1

50%

0.02756347

1740

2

25%

0.01378173

1830

3

12.5%

0.00689086

1920

4

6.25%

0.00344543

2010

5

3.125%

0.00172271

2100

6

1.5625%

0.00086135

2150

7

0.78125%

0.00043067

Percent of bioavailable drug returns to 100 with each injection.
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CHAPTER II
METHODS

5.1 Animals

A total of 60 female and 30 male, adult nulliparous Sprague-Dawley rats, were
acquired from Harlan Industries, Inc. (Indianapolis, IN). All rats were transported to the
animal care facilities in the psychology department at the University of South Carolina
and rodent food (ProLab Rat/Mouse/Hamster Chow 3000) and water were provided ad
libitum throughout the course of the experiments. The animal colony was maintained at
21 ± 2° C, 50% ± 10% relative humidity and a 12L:12D cycle with lights on at 0700 h.
All animal cages were provided with Nylabones (Nylabone, Inc.; Neptune, NJ)
and Nestlets (NestletsT; Ancare, Bellmore, NY) for environmental enrichment. A
Nylabone was replaced if it is thoroughly chewed, and one Nestlet nesting product was
placed in each cage when the cage is changed for sanitation, which occurred 2×/week.
This experimental protocol was approved by the Institutional Animal Care and Use
Committee at the University of South Carolina.
5.1.1 Internalized jugular catheter surgeries

The internalized jugular catheters that were implanted in the dams are
commercially available from Harlan Industries (Indianapolis, IN), where the
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catheterization procedure was performed according to the methods of Mactutus et al.
(1994), prior to arrival in the colony at the University of South Carolina. In summary,
animals were anesthetized with a mixture of ketamine hydrochloride (100 mg/kg/ml) and
xylazine (3.3 mg/kg/ml).
Following anesthesia, a sterile Intracath IV catheter (Becton, Dickinson and Co.,
Franklin Lakes, NJ) with a Luer-Lok injection cap (Medex, Inc., Carlsbad, CA) was
implanted dorsally in a subcutaneous pouch. The distal end of the catheter was inserted
into the left jugular vein, advanced toward the heart, and bound with a sterile suture.
Animals were kept under post-operative observation and returned to the colony upon
recovery. The day after surgery, catheters were flushed with 0.2 ml of heparinized saline.

5.1.2 Breeding

Upon arrival, all animals were habituated to the colony room for 7 days.
Following the habituation period, female rats were housed three per cage and one male
were placed in the cage, overnight, from approximately 1700 to 0900 for the purposes of
breeding.
Lavage samples were acquired from each female every morning and vaginal
cytology recorded using a low-magnification objective on a standard Nikon microscope.
On the day sperm was detected, the dams were single-caged. Day of sperm-positive
lavage sample was gestational day (GD)0.
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5.2 Drugs

Nicotine hydrogen tartrate (Sigma-Aldrich Pharmaceuticals; St. Louis, MO) was
weighed as base and dissolved in physiological saline (0.9%; Hospira, Inc. Lake Forest,
IL).
The pH of the nicotine solution was neutralized to ~ 7.0. Heparin (APP
Pharmaceuticals, Schaumburg, IL) was added to saline and the heparinized saline
solution (2.5%) was used to flush the IV catheters.

5.2.1 Prenatal Nicotine Treatment

Pregnant dams were randomly assigned to either the PN (0.05 mg/kg/injection) or
PS groups. Nicotine or saline was administered 3×/day from gestational days (GD) 8-21.
Following the first two daily injections, catheters were flushed with 0.2 ml of 0.9%
physiological saline, and heparinized saline (2.5%) were used to flush the catheter after
the final daily NIC or SAL administration. Injections will occur at 1000, 1300, and 1600
daily.

5.3 Surrogate Fostering, Litter Composition, and Postnatal Testing

Post-natal day (PND) 0 was recorded when pups were found in the cage. On PND
1, Litters were culled 10 pups with 5 males and 5 females whenever possible. All pups
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were surrogate-fostered to timed-pregnant, drug naïve dams to prevent poor maternal care
on PND 1 (Vorhees, 1986).
Offspring were weaned and pair housed, same sex, on PND 21. Behavioral
developmental milestones were assessed as follows: righting reflex (PND 3-5), negative
geotaxis (PND 8-10) eye opening (PND 13-17), (Heyser, 2004). Subjects were sacrificed
either on PND 10 or PND 35; data provided for developmental milestones reflect
assessments for righting reflex and negative geotaxis for the first group; the second (PND
35) group has representative data for all three developmental milestone behavioral
assessments.
The righting reflex assessment was conducted in blocks of 3 trials on 3
consecutive days. Briefly, pups were placed on their backs, and the length of time it will
take the animals to right themselves onto their stomachs was recorded, with a maximum
latency of 25 seconds per trial. Negative geotaxis was measured in blocks of 3 trials
across 3 consecutive days. For this task, pups were placed with their heads towards the
ground on a wire mesh grid positioned on a 25° downward angle. The latency (30 second
maximum) for the animals to turn 180° to face up the slope was measured.
Eyes were checked for degree of openness across 5 consecutive days. The degree
of openness was rated on a scale of 0-3: 0 = completely closed; 1 = any opening exposing
the cornea; 2 = cornea and pupil exposed but eye lids are not fully open; 3 = fully open.
All animals’ weights were recorded on PND 1, 7, 14, and 21. Rats were weaned and pair
housed, same sex, on PND 21.

37 36

5.4 Nicotinic Receptor Autoradiography

10 males (5 PS, 5PN) and 10 females (5PS, 5PN) were sacrificed via rapid
decapitation on postnatal day 10. A second group of 10 males (5 PS, 5 PN) and 10
females (5PS, 5PN) was sacrificed via rapid decapitation on postnatal day 35 (see Table
2, Figure 2). Radioligand binding produced expression densities for the PFC,
Hippocampus, NAc, VTA, and PPTg.

5.4.1 Nicotinic Receptor Autoradiography: α4β2 nAChR

Tissue was prepared prior to ligand application: first, a Krebs-Ringer HEPES
(KRH, pH 7.5) buffer solution of 4.8mM KCI, 2.5 mM CaCI2, 1.2 mM MgSO4, 118mM
NaCI, 20mM hepes and 10mM NAOH was used to incubate slides for 40 min. at room
temperature.
Following this, a separate KRH solution served as incubation for 90 minutes at
room temperature to facilitate ligand binding: [125I]-epibatidine (100 nM 2200 Ci/mmol).
The slides were rinsed in chilled KRH buffer (4°C, 2x). RayMax Beta High Performance
Autoradiography Film (ICN Biomedicals, Aurora, Ohio) was used to visualize ligand
binding. Exposure time was 3 days for [125 I]-epibatidine (Table 3).

5.4.2 Nicotinic Receptor Autoradiography: α7 nAChR
Whole brains were flash frozen in isopentane (–35°C). Samples were stored at –
70°C for at least 24h. On a cryostat, brains were sectioned (~16µm) and mounted on
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gelatin-and chrom alum coated slides. For [125I]-bungarotoxin autoradiography, a KrebsRinger HEPES (KRH, pH 7.5) buffer solution of 4.8mM KCI, 2.5 mM CaCI2, 1.2 mM
MgSO4, 118mM NaCI, 20mM hepes and 10mM NAOH was used to incubate slides for
30 min. at room temperature. Following this, a separate KRH solution will serve as
incubation for two hours at room temperature to facilitate ligand binding: 2.5nM α-[125I]Tyr54-BTX (specific activity:102.9 Ci/nmol on day of binding) under equilibrium
binding conditions.
The slides were rinsed in chilled KRH buffer (4°C, 2x), diluted KRH buffer 1x,
and deionized H2O 1x, respectively. Nonspecific blanks were assayed with 10 mM LNicotine, without exceeding film background (Pauly & Collins, 1993). Samples were
kept at room temperature in a desiccator overnight, exposed to RayMax Beta highperformance autoradiography film (ICN Biomedicals Inc., Aurora, OH) for 14 days
(Table 3).

5.4.3 Nicotinic Receptor Autoradiography: α6 nAChR

Before incubation with [125 I]α-CtxMII, sections were incubated in binding buffer
(144 mM NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 20 mM HEPES, 0.1% BSA
(w/v), pH 7.5) phenylmethylsulfonyl fluoride (1 mM, to inactivate endogenous serine
proteases) at 22°C for 15 min. For all [125 I]α-CtxMII binding reactions, the standard
binding buffer was supplemented with BSA [0.1% (w/v)], 5 mM EDTA, 5 mM EGTA,
and 10 g/ml each of aprotinin, leupeptin trifluoroacetate, and pepstatin A to protect the
ligand from endogenous proteases. The sections were then incubated with 0.5 nM [125

39 38

I]α-CtxMII for 2h at 22°C. After incubation with [125 I]α-CtxMII, the slides were washed
as follows: 30 sec in binding buffer 0.1% (w/v) BSA (22°C), 30 sec in binding buffer
0.1% (w/v) BSA (0°C), 5 sec in 0.1 binding buffer 0.01% (w/v) BSA (twice at 0°C), and
twice at 0°C for 5 sec in 5 mM HEPES (pH 7.5) (Table 3).

5.5 Collecting Luminance Values

All autoradiography slides were digitally analyzed using the software program
Densita (MicroBrightField, 2014; MBF), to outline brain regions of interest and labeled
radioligand density. The MBF Densita platform was used to calculate ‘luminance’ values
(as the dependent variable), with ‘luminance’ indicating density of receptors.
Because the autoradiograms do not have traditional standards, each image was
loaded into the Densita program as total binding (for each section), and a gray scale
image with values from 0 (darkest, almost black) to 250 (lightest, almost white) will
provide a linear black-to-white gradient for comparison (see Figure 1). Luminance
values are based on comparing the shade, or gradient, of the region of interest to the gray
scale spectrum. This is the “Step Wedge” method in the MBF Densita program.
Using Step Wedge, high luminance values indicate lower density, and low
luminance values indicate a greater density of radioligand binding for the labeled receptor
(Figure 2). All cortical tissues analyzed for luminance include information about which
laminar layer density measures were taken from. Each report of outcome data for a given
brain area also includes information about the location of the slices, relative to Bregma.
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5.6 Data Analysis
5.6.1 Litter Parameters

Litter parameters were analyzed with the following factors: treatment (2) as the
between-subjects factor; within-subjects factor of gestational day (4) –dam weight gain
for gestational days: 0, 7, 14, and 21; for pup weight gain, within-subjects factor of
postnatal day (4) pup weight gain neonatal days: 0, 7, 4, 21. A 2 × 4 Treatment ×
Gestational Day mixed ANOVA was used to ascertain any differences between PN and
PS dams on the measure of dam weight gain, and a 2 × 4 Treatment × Postnatal Day
mixed ANOVA was used to analyze offspring weight gain.
One-way ANOVAs with Treatment (2) as the between-subjects factor analyzed
number of male offspring born, as well as number of female offspring born, followed by
a Chi-Square test to compare the ratio of males to females born to PN and PS dams. Sex
× Treatment × Postnatal Day mixed-factorial ANOVAs were performed for pup weight
gain, righting reflex, negative geotaxis and eye opening data. A Kruskall-Wallis test
analyzed each day of eye-opening, with Treatment as grouping factor.

5.6.2 Preliminary One-way ANOVA: Litter as a Random Subject effect

For this experiment, four rats were used per dam (Litter), for a total of 40 subjects
from 10 dams. The random Litter variable can confound data interpretation, and threaten
the statistical assumption of independence (Aart et al., 2014) (Figure 2).
Litter of origin is a random subjects effect, because each dam has an equal
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likelihood of being selected at random from the population of possible dams (Gamst,
Meyers & Guarino, 2008). Each Litter is ‘nested’ within each Treatment group, and each
of the 40 subjects is then ‘nested’ within its Litter of origin (Figure 2).
To determine the relative contribution of Litter to the variability of distribution of
Luminance values, multilevel modeling (also called nested modeling, hierarchical linear
modeling, mixed linear modeling, and random-effects modeling) techniques can
determine an estimate of dependence (Aart et al., Moen et al., SPSS, 2014). In SPSS, the
procedure for multilevel modeling with random effects, is the Mixed Models Linear
(MML) procedure. With MML, Litter is entered into the model as a random “subjects”
factor, indicating the random effect is a sampling effect.
To determine if data should be modeled with Litter as a random subject effect, a
preliminary one-way ANOVA with a conservative alpha level of p< 0.25 was ran for
each dataset; (F=MSlitters/MSsubjects; Denenberg, 1976). For each preliminary one-way
ANOVA, the Ho: no Litter effect. If Ho was rejected, then data analysis proceeded with
an MML analysis in SPSS. If the Ho was not rejected, data analysis proceeded with
Univariate ANOVA in SPSS (see sections 6.2 and 6.3 below).
According to Tabachnick & Fidell, (2013), as well as Denenberg (1976), the oneway ANOVA test is an appropriate first step of data analysis with Litter effects. If the Ho
was rejected, variance results produced by the MML analysis allowed calculation of the
IntraCluster Correlation (ICC); which is labeled in the results section with the Latin
symbol for rho, “r”. In multilevel modeling, the ICC is a measure of random (Litter)
effect.
The MML procedure in SPSS produces variance estimates between groups, as
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well as variance estimates within Litter groups, and this data was used to calculate an
estimate of the ICC. ICC was calculated to estimate how much of the variance is
associated with the Litter Variable, as a next step in MML analysis. The ICC is calculated
using the Estimates of Covariance Parameters from the linear mixed models analysis:

Variability between groups
ICC =

--------------------------------------------- X

100

Variability between groups + Variability within (Litter) groups

Litter was entered as the random subject variable for the mixed models MML, and
the fixed models in MML analysis were as follows: Treatment, Sex, and Age, and
interactions of those variables, (when available. Some datasets only contained images
available for densitometry from the adolescent subjects. In those cases, Age was not a
factor). The MML used Sum of Squares III. Both fixed and random effects models
included the intercept, and used the Variance Components covariance structure.

5.6.3 Mixed Models Linear Analysis: Luminance

Because of the nested experimental design, if the Ho from the initial analysis is
rejected, Luminance values were analyzed in a Mixed Models design, with Litter as
random effect. For data collected on each brain region expressing the nAChR of interest,
a 2 × 2 × 2 × 10 MML (SPSS 23) was done, with Treatment (2), Sex(2), and Age(2) as
fixed factors, and Litter(10) as random factor.
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MML is a variation of regression analysis, but MML allows for random intercepts
and slopes (Tabachnick & Fidell, 2013), adjusted so that fixed effects contribute to the
primary sources of variability of the DV, but random effects influence the covariance
structure. In MML, the responses (of the rat) are the sum (i.e., linear) of the fixed and
random effects models’ entered into the analysis.
MML analysis considers the variances that are unequal, and weights the variance
contributed by effects to the linear model. In the SPSS (IBM) statistical software, the
MML procedure treats Litter as a random “subjects” variable. The adjustment of
covariance in a standard general linear model or univariate ANOVA isn’t sufficient,
because structurally, both procedures still assume the independence of data (SPSS 2002).
Additionally, MML in SPSS is a more appropriate statistic when the Litter has
significant influence on the variability of the DV, because of the estimation procedure. In
the Univariate ANOVA, the outcome is predicated on a balanced design, and the
estimation produced is based only on a minimum variance model.
In SPSS, MML variance estimations are based on either maximum, or restricted
maximum likelihood (ML, REML)—estimations modeled on asymptotic normality, and
the estimates of covariance parameters predict the DV score for each individual (rat) by a
random intercept that varies across groups (Litters), (Gamst et al, 2008; SPSS 2002;
Tabachnick & Fidell 2013). For the sake of uniformity, the results section (Chapter III)
will report MML analysis with each significant fixed effect model (p-values were
obtained by likelihood ratio tests of the full model with the effect in question, against the
model without the effect in question) using the same basic structure as the ANOVA
results—that is, [Fixed effect (dfbetween, dferror) =____ , p=_____], h2, post-hoc power = .

44 43

5.6.3.1 MML Effect Size Calculation

Lastly, the estimate of effect size is typically a challenging statistic to procure
when using multilevel modeling. The ANOVA produces partial ƞ2, but MML analysis
typically is more complex and the effect size estimation is not generated by SPSS. The
effect size for the MML results (Chapter III) are calculated here using the error variance,
which can increase as fixed and random variables are added to the multilevel model
(Kreft & DeLeeuw, 1998).
For the brain regions and nAChR subtypes using MML analysis, the effect size is
calculated as follows (from Kreft & DeLeeuw, 1998; and Tabachnick & Fidell, 2013):

ƞ2 = !12 – !22
_____________________
!1 2

!12
!22

is the Residual variance of
the Intercepts-only model
is the residual variance of
the fixed effect

In this calculation, the effect size is calculated using portions of the mixed model
analysis. This is conceptually similar, but calculated differently, from the ICC and ƞ2
produced from the Univariate ANOVA; those measures of effect size evaluate the
difference in variances between- and within-groups without consideration of the randomeffects.
For confirmation of the validity of the ƞ2 calculated in the Results section for
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MML analysis (Chapter III), each time a ƞ2 was calculated, the entire dataset was
analyzed a second time using standard Univariate ANOVA. The partial ƞ2 produced by
the factorial ANOVA was compared to the ƞ2 calculated from the MML analysis
variance estimates, to make certain the calculations were within a hundredth of a point of
each other.

5.6.4 Univariate ANOVA: Luminance & Relative Optical Density

If Ho from the preliminary one-way ANOVA is not rejected, datasets for each
brain region expressing an nAChR of interest were analyzed with a 2 × 2 × 2 factorial
ANOVA with Treatment, Sex, and Age as between-subjects factors for the Luminance
variable. Interactions were also entered into the ANOVA analysis, comparing Treatment
× Sex, Treatment × Age, Sex × Age, and Treatment × Sex × Age.
Each ANOVA also produced means and SEMs for each main effect, across brain
region and nAChR type (Tables X-X), F-ratios, significance values and partial ƞ2. (Data
analyses for MML, one-way ANOVA, and Univariate ANOVA, were produced using
SPSS 23 (IBM Software), and graphs were generated with Graphpad Prism 6 (Graphpad
Software, Inc.).

5.6.5 Power Analysis

The power (1-β) for each significant main or interaction effect from the MML or
factorial ANOVA was calculated using G*Power 3.1.9.2 (Heinrich Heine, Universität
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Düsseldorf). With the G*Power software, the power statistic for each significant effect
was determined post-hoc; 1-β was computed as a function of the ANOVA or MML α,
effect size, and sample size.
The G*Power software is also chosen because it allows effect size to be included
either either by direct entry of partial ƞ2, (as is obtained from the factorial ANOVA), or
by inputting the ‘variance explained by special effect’ and ‘error variance,’ (as is
obtained from the MML analysis) into the power calculator. Using either of these effect
size estimates enables G*Power to produce the actual power of the statistical model.

Table 2.1 Age, sex and treatment group assignment.
Post Natal Day

Group

Sex
Male =5

PS n =10

Female = 5

10

Male = 5
PN n =10

Female = 5
Male =5

PS n =10

Female = 5

35

Male =5

PN n =10

Female = 5
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Table 2.2. Three radioligands used to detect putative nAChRs.

Radioligands used to assess nicotinic acetylcholinergic receptors (nAChRs) markers in rat brains of
offspring exposed to prenatal nicotine or saline.
Ligand

Concentration

Native venom origin of
synthetic ligand

Detects

[125I]-epibatidine

100 nM

Epipedobates anthonyi –
Ecudorian frog

a4β2 nAChRs

[125I]-bungarotoxin

2.5nM

Bungarus multicinctusTaiwanese krait snake

α7 –containing
nAChRs

[125I]-conotoxin MII

0.5 nM

Conus Magus- Cone sea
snail

α6 –containing
nAChRs

Radioligands used to assess nicotinic acetylcholinergic receptors (nAChRs) markers in rat brains of
offspring exposed to prenatal nicotine or saline.
Ligand

Concentration

Native venom origin of
synthetic ligand

Detects

[125I]-epibatidine

100 nM

Epipedobates anthonyi –
Ecudorian frog

a4β2 nAChRs

[125I]-bungarotoxin

2.5nM

Bungarus multicinctusTaiwanese krait snake

α7 –containing
nAChRs

[125I]-conotoxin MII

0.5 nM

Conus Magus- Cone sea
snail

α6 –containing
nAChRs
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Figure 2.1 Gray Scale binding reference. Gray scale from Step Wedge procedure in
MicroBrightField Densita. “Zero” indicates the darkest color, with 11 gradients
increasing in numerical units of 25 (0, 25, 50, 75, 100, 125, 150, 175, 200, 225,
250), and ranging from dark-to-light (0=black, center gray=125, lightest=250).
Each pixel within each of the 11 boxes on the gray scale is mapped to a specific
color, with a luminance value associated with that pixel. The generated
autoradiograph images of brain sections are loaded into Densita as .jpg
pictomicrographs. Pixels of the selected brain area are compared to the
standardized gray scale. Luminance data is generated when a brain area is
selected, contoured for accurate shaping, and finalized for analysis.
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Prenatal Nico-ne Treatment

Prenatal Saline Treatment

Level II

♀

Level I

♀

♀
♀

♀
♀

♀

♀
♀

♀

10 day olds

35 day olds

Male
Female

Figure 2.2 Graphical representation of research objects and observations in dataset.
N=10 dams/litters (N=5 prenatal nicotine litters, N=5 prenatal saline litters) each
litter contributed one male and one female (2 subjects) on postnatal day 10, and
again (2 subjects) on postnatal day 35.
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CHAPTER III
RESULTS

6.1 Litter Parameters

Analysis of the maternal weight gain revealed a significant main effect of
gestational day [F(3, 81) = 754.36, p = 0.000] partial h2= 0.98; with all dams increasing
weight throughout gestation. The ANOVA revealed no significant main effect of
maternal treatment, and no interaction between maternal treatment and gestational day, as
illustrated in Figure 3a.
There was no Treatment effect for number of female offspring produced, [F(1,
8)= 0.259, p= 0.171] (Figure 4), or male offspring produced, [F(1, 8)= 0.031, p= 0.864]
(Figure 4) nor difference in the ratio of males to females, c2= 15.69, p = 0.403, or total
number of pups born between prenatal treatments, [F(1, 8)= 0.459, p= 0.517], (Figure 4).
A significant effect of postnatal day, [F(3, 81)= 654.86, p= 0.000] partial h2=
0.996 indicated all pups gained weight consistently across the three postnatal weeks
(Figure 3b). No Treatment effect was found for neonatal weight gain, [F(3, 36)= 1.89, p=
0.119] (Figure 3b). The main effect of Sex was not significant for postnatal weight gain
[F(3, 36)= 1.02, p= 0.388].
The analysis of Righting Reflex latency showed a significant main effect of
postnatal day, [F(2, 72) = 41.87, p = 0.000], as all offspring reduced the latency to
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complete the reflex behavior across three consecutive days of testing. There were no
significant main effects of Treatment [F(2, 72) = 0.070, p = 0.993] (Figure 5a), or Sex,
[F(2, 72) = 2.22, p = 0.114], and no interaction, for latency to perform the Righting
Reflex.
A significant effect of postnatal day was found for negative geotaxis [F(2, 72) =
7.00 p = 0.002] partial h2= 0.209, post hoc power=1.00, indicating all offspring improved
latency to perform the Negative Geotaxis task, across the consecutive days of testing with
increasingly shorter latencies to face up the inclined apparatus: Day 8 (M= 8.88 ± 0.517),
Day 9 (M= 7.19 ± 0.347), Day 10 (M= 6.23 ± 0.501) (Figure 5b). Neither Treatment nor
Sex had a significant main effect on Negative Geotaxis latency, [F(2, 72) = 1.71, p =
0.196]; [F(1, 72) = 0.101, p = 0.752], respectively; nor was the interaction significant.
Note: statistical analyses of Eye Opening data only included N= 20 offspring. The
total N = 40 offspring in these experiments, but n =20 were sacrificed at postnatal day 10
(representing the neonatal Age group), and Eye Opening is assessed on postnatal days 1317. The ANOVA analysis of Eye-Opening data revealed a significant main effect of Day,
[F(2, 108) = 172.22, p = 0.000], but no significant main effects of Treatment [F(1, 108) =
.665, p = 0.420], or Sex [F(1, 108) = .079, p = 0.780], or interaction, across days of eye
opening.
The Kruskall-Wallis test revealed no significant differences between Treatment
groups for eye opening as follows: Day 13: [H(2) p= 0.317], Day 14, [H(2) p= 1.00], Day
15 [H(2) p= 0.418], Day 16, [H(2) p= 0.278], Day 17 [H(2) p= 0.139], indicating that
there were no significant differences in eye opening between groups.
** For the remainder of the results section: significant findings, which are underpowered,
are reported (with power estimate) and double asterisk **. However, significant but
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underpowered interactions did not undergo further probative statistical investigation.

The Results Section also includes data analysis for those brain regions
which did not undergo hypothesis testing: Substantia Nigra, Dorsal
Striatum, Basolateral Amygdala, Cingulate Cortex (Anterior), Medial
Habenula, Interpeduncular Nucleus, Raphe Nucleus, Insular (agranular)
Cortex, Auditory Cortex, Motor Cortex, Parietal Cortex, and Somatosensory
Cortex.
6.2 Mesocorticolimbic Dopamine Circuit: VTA, NAc, PFC

6.2.1 [125 I]-epibatidine (Table 3)

VTA: The preliminary between-subjects one-way ANOVA revealed no significant
effect of Litter [F(9, 29)=1.221, p=.321)], so data analysis proceeded with the betweensubjects factorial ANOVA. The analysis revealed a significant effect of Treatment [F(1,
31)=8.40, p=0.007, partial ƞ2=0.213, post-hoc power=0.89 (Table 4a; Figure 6). Neither
Sex nor Age were significant main effects (Tables 4b&c) and no significant interactions
were found.
NAc: The preliminary between-subjects one-way ANOVA revealed a significant
effect of Litter [F(9, 31) = 1.43, p = 0.220], so a MML analysis followed. Results of the
MML analysis provided variance information to compute the ICC (by hand, using
formula in section 4.3.2); r = 0.316; indicating Litter constitutes 31.6% of the variability
across subjects and fixed effects.
The MML analysis revealed a significant fixed effect of Treatment, [Fixed Effect
(1, 32) = 12.71, p = 0.001, ƞ2 =0.194, power = 0.85 (Table 4a; Figure 7). No significant
main effects or interactions were found for Sex or Age (Tables 4b&c).
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PFC: The prefrontal cortex is labeled “Frontal Cortex,” in the 6th ed. Rat Brain
Atlas (Paxinos & Watson, 2006). A preliminary between-subjects one-way ANOVA
revealed no significant effect of Litter, [F(9, 30) = 0.354, p = 0.947], so the analysis
proceeded with a between-subjects factorial ANOVA.
There was no significant main effect of Treatment (Table 4a), but significant main
effects of Sex [F(1, 31) = 9.40, p = 0.004], partial ƞ2=0.233, post-hoc power=0.92 (Table
4b), and Age [F(1, 31) = 50.93, p = 0.000], partial ƞ2=0.622, post-hoc power=1.00 (Table
4c) and a significant but unpowered, Sex × Age interaction [F(2, 31) = 7.74, p = 0.009]
ƞ2=0.200, post-hoc power=0.69** was found. For this ligand, the Frontal cortex data was
collected using the most rostral slices available, where the labeling appeared in the
deepest laminar layer (V/VI) for both neonatal rats. In adolescents, layers III and VI were
labeled and data collected from the Frontal cortex.

6.2.2 [125I]-α bungarotoxin (Table 3)
VTA: Densitometry measurements were not possible for [125I] α-bungarotoxin
binding in the VTA.
NAc: The preliminary one-way ANOVA revealed no significant effect of Litter,
[F(9, 31)= 0.853, p=0.575], so the analyses continued with a between-subjects factorial
ANOVA, revealing a significant main effect of Treatment [F(1, 32)= 7.59, p=0.010]
partial ƞ2= 0.192, post-hoc power= 0.83 (Table 5a; Figure 13), but no significant effects
of Sex or Age (Tables 5a&b), or interactions of Sex or Age with Treatment.
However, a significant but unpowered Sex × Age interaction was revealed [F(3,
32)=8.17, p=0.007] partial ƞ2= 0.203, post-hoc power= 0.70**.
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PFC: Densitometry measurements were not possible for [125I] α-bungarotoxin
binding in the Frontal Cortex.

6.2.3 [125 I]α-CtxMII (Table 3)

VTA: [125 I]α-CtxMII binding was visible only in the adolescent pictomicrographs
(postnatal day 35). The preliminary one-way ANOVA revealed no significant effect of
Litter, [F(9, 11)= 1.26, p=0.379], so the analysis proceeded with between-subjects
factorial ANOVA.

The ANOVA revealed a significant but unpowered main effect of

Treatment, [F(1, 16)=6.84, p=0.020] partial ƞ2=0.328, post-hoc power=0.78** (Table
6a), no significant main effect of Sex (Table 6b); but a significant, unpowered, interaction
of Treatment × Sex, [F(2, 16)= 5.93, p=.029] partial ƞ2= 0.297, post-hoc power= 0.50**.
NAc: [125 I]α-CtxMII binding was visible only in the adolescent pictomicrographs
(postnatal day 35). The preliminary one-way ANOVA revealed no significant Litter
effect, [F(9, 11)= 1.53, p=0.332], and analyses proceed with between-subjects factorial
ANOVA. However, no significant main effects or interactions of Treatment and/or Sex
were revealed (Tables 6a&b).
PFC: [125 I]α-CtxMII binding did not occur in the Frontal Cortex.

6.3 Nigrostriatal Dopamine Circuit: Substantia Nigra and Dorsal Striatum
6.3.1 [125I]-epibatidine (Table 3)
Substantia Nigra: The preliminary one-way ANOVA revealed no significant
effect of Litter, [F(9, 29)= 0.637, p= 0.756], so analyses proceeded with between-
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subjects factorial ANOVA. However, the analyses revealed no significant effects or
interactions of Treatment, Sex, or Age (Table 4a, b&c).
Dorsal Striatum: The preliminary one-way ANOVA revealed no significant
effects of Litter, [F(9, 29)= 0.187, p=0.994], so the analyses continued with betweensubjects factorial ANOVA. A significant main effect of Treatment [F(1, 30)= 8.41,
p=0.007] partial ƞ2= 0.213, post-hoc power=0.88 (Table 4a; Figure 8); as well as a
significant main effect of Age [F(1, 30)= 202.97, p=0.000] partial ƞ2= 0.868, post-hoc
power= 1.00 (Table 4c), was revealed, but no interaction between the two factors, and
Sex was not a significant factor (Table 4b).

6.3.2 [125I] α-bungarotoxin (Table 3)

Substantia Nigra: [125I] α-bungarotoxin binding only visible in the adolescent
pictomicrographs (postnatal day 35). The preliminary one-way ANOVA revealed a
significant effect of Litter [F(9, 11)= 1.62, p=0.243]. Luminance values were then
analyzed with an MML analysis; the ICC generated was r= 0.1539, or 15.39% of the
variance in the model was explained by Litter. Fixed effects of Treatment and Sex were
not statistically significant, (Tables 5a&b), and analyses were concluded.
Dorsal Striatum: visible [125I] α-bungarotoxin binding was visible only in the
adolescent pictomicrographs (postnatal day 35). The preliminary one-way ANOVA
revealed no significant effect of Litter [F(9, 11)= 0.856, p=0.587], so the analyses
proceeded with between-subjects ANOVA, revealing no significant main effects of
Treatment or Sex (Tables 5a&b), and no significant interaction.
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6.3.3 [125 I]α-CtxMII (Table 3)
Substantia Nigra: The preliminary one-way ANOVA revealed no significant
effect of Litter, [F(9, 31)= 0.326, p= 0.957], so the analyses proceeded with betweensubjects factorial ANOVA. Treatment (Table 6a) was not a significant effect, nor was
Sex (Table 6b). The ANOVA did reveal a significant main effect of Age, [F(1, 32)=
108.43, p=0.00] partial ƞ2= 0.819, post-hoc power= 1.00 (Table 6c). No interactions were
significant.
Dorsal Striatum: [125 I]α-CtxMII binding was visible only in the adolescent
pictomicrographs (postnatal day 35). The preliminary one-way ANOVA revealed no
significant effect of Litter [F(9, 11)= 0.790, p=0.634], so the analyses proceeded with
between-subjects factorial ANOVA, revealing no significant effect of Treatment (Table
6a), but an unpowered significant main effect of Sex, [F(1, 16)= 6.94, p=0.019] partial
ƞ2=0.316, post-hoc power= 0.79** (Table 6b). No significant effect of the treatment by
sex interaction.

6.4 Pedunculopontine Tegmental Nucleus
6.4.1 [125I]-epibatidine (Table 3)

PPTg: The preliminary one-way ANOVA revealed no significant effect of Litter,
[F(9, 30)= 0.326, p=0.959], so the analyses proceeded with between-subjects factorial
ANOVA, revealing no significant effects of Treatment or Sex (Tables 4a&b), but a
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significant main effect of Age [F(1, 31)= 38.71, p=0.000] partial ƞ2= 0.563, post-hoc
power= 0.99 (Table 4c) is evident. None of the interactions were statistically significant.

6.4.2 [125I] α-bungarotoxin (Table 3)
PPTg: [125I] α-bungarotoxin binding was visible only in the adolescent
pictomicrographs (postnatal day 35). The preliminary one-way ANOVA revealed a
significant effect of Litter [F(9, 11)= 4.69, p=0.015], and further main effects and
interactions were investigated with MML analysis. The ICC was calculated, r= 0.6590;
indicating 65.90% of the variability of Luminance values is attributed to Litter. There
were no main effects of Treatment or Sex (Tables 5a&b), and no interaction of the two
factors.

6.4.3 [125 I]α-CtxMII (Table 3)
PPTg: No [125 I]α-CtxMII binding was visible in the PPTg.

6.5 Extended Reward Neurocircuitry: Hippocampus, BLA, Cingulate Cortex

6.5.1 [125I]-epibatidine (Table 3)
Hippocampus: No visible [125I]-epibatidine binding was evident in the
hippocampus.
BLA: The preliminary one-way ANOVA revealed a significant effect of Litter,
[F(9, 31) = 1.64, p = 0.149] and was followed up with MML analysis. From this MML
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analysis, the ICC was computed; r= 0.637, indicating Litter is responsible for 63.7% of
the variability in the distribution of luminance values.
MML analysis revealed a significant unpowered effect of Treatment, [F(1, 32) =
6.48, p=0.016 ] partial h2= 0.142, post-hoc power = 0.70** (Table 4a) Age and Sex did
not have significant effects (Tables 4b&c), and no interaction was significant.
Cingulate Cortex: The preliminary one-way ANOVA revealed no significant
effect of Litter, [F(9, 31) = 0.398, p = 0.926], so analysis continued with a betweensubjects ANOVA. The ANOVA revealed a significant effect of Treatment [F(1, 32) =
7.68, p =0.009] partial h2= 0.194, post-hoc power = 0.85 (Table 4a; Figure 9); a
significant but unpowered effect of Sex [F(1, 32) = 4.51, p =0.042] partial h2= 0.123,
post-hoc power = 0.63** (Table 4b); a significant effect of Age [F(1, 32) = 42.32, p
=0.000] partial h2= 0.569, post-hoc power = 0.99 (Table 4c); significant but unpowered
interactions between Sex × Age [F(2, 32) = 4.13, p =0.050] partial h2= 0.114, post-hoc
power = 0.40**, as well as an unpowered three-way interaction of Treatment × Sex ×
Age [F(3, 32) = 5.85, p =0.021] partial h2= 0.154, post-hoc power = 0.32**. For the
Cingulate cortex, this ligand was labeled mostly in the deepest cortical layer for both age
groups (laminar layer V/VI).

6.5.2 [125I] α-bungarotoxin (Table 3)
Hippocampus: The preliminary one-way ANOVA revealed a significant effect of
Litter, [F(9, 31)= 2.46, p=0.031], so MML analysis was used for main effects and
interactions. The MML analysis provided information to generate the ICC; r= 0.126,
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indicating the Litter variable accounted for 12.6% of variance in the distribution of the
Luminance DV.
MML analysis revealed a significant main effect of Treatment, [F(1, 32)= 17.89,
p=0.000] partial ƞ2= 0.229, post-hoc power= 0.91 (Table 5a; Figure 14). Sex did not have
a significant main effect (Table 5b), but Age was a significant, unpowered main effect
[F(1, 32)= 11.54 p=0.002] partial ƞ2= 0.101, post-hoc power=0.54** (Table 5c). No
significant interactions were revealed.
BLA: The preliminary one-way ANOVA revealed no significant effect of Litter,
[F(9, 31)= 0.663, p=0.735], and the analysis continued with a between-subjects factorial
ANOVA. The ANOVA revealed no significant effect of Treatment (Table 5a), but Sex
had a significant main effect, [F(1, 32) = 8.31, p =0.007] partial h2= .206, post-hoc power
= 0.87 (Table 5b). No significant effect of Age was found (Table 5c), but a significant
unpowered interaction of Treatment and Age [F(2, 32) = 4.19, p =0.049] partial h2= .116,
post-hoc power = 0.41**.
Cingulate Cortex: The preliminary one-way ANOVA revealed significant effect
of Litter, [F(9, 31) = 1.44, p =0.314], so the factorial ANOVA was performed; the
ANOVA revealed a significant Treatment effect, [F(1, 32) = 7.27, p =0.011] partial h2=
.185, post-hoc power = 0.81 (Table 5a; Figure 15), but Sex was not a significant main
effect (Table 5b). Age was a significant main effect, [F(1, 32) = 11.78, p= 0.002]
partial h2= .269, post-hoc power = 0.96 (Table 5c). No interactions reached statistical
significance. For this ligand, the Cingulate Cortex was labeled most intensely in layers III
and IV; density measurements reflect labeling in layers III and IV.
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6.5.3 [125 I]α-CtxMII (Table 3)
Hippocampus: No [125 I]α-CtxMII binding was evident in the hippocampus.
BLA: No visible [125 I]α-CtxMII binding was capable of densitometry analysis.
Cingulate Cortex: No [125 I]α-CtxMII binding was evident in the Cingulate
Cortex.

6.6 Cholinergic pathway: Medial Habenula, Interpeduncular Nucleus, Raphe
Nucleus

6.6.1 1 [125I]-epibatidine (Table 3)
Medial Habenula: The preliminary one-way ANOVA revealed no significant
effect of Litter, [F(9, 31)= 1.13, p=0.374], so the analyses proceeded with a betweensubjects ANOVA: Treatment was revealed as a significant, but unpowered main effect,
[F(1, 32)= 4.80, p =0.036] partial h2= 0.130, post-hoc power=0.660** (Table 4a).
Sex was not a significant main effect (Table 4b); Age emerged as significant
unpowered effect, [F(1, 32)= 4.17, p= 0.050] partial ƞ2= 0.115, post-hoc power= 0.599**
(Table 4c). A significant, unpowered interaction of Sex × Age [F(2, 32)= 7.63, p=0.009]
partial ƞ2=0.192, post-hoc power= 0.753**.
Interpeduncular Nucleus: The preliminary one-way ANOVA revealed no
significant effects of Litter [F(9, 31)= 0.591, p=0.794], so the analysis proceeded with a
between subjects ANOVA, which revealed no significant effects of Treatment (Table 4a),
Sex (Table 4b), or Age Table 4c), but a singular significant unpowered interaction
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between Treatment × Age, [F(1, 32) = 4.08, p =0.052] partial h2= 0.113, post-hoc power
=0.39**.
Raphe Nucleus: [125I]-epibatidine binding was was visible only in the adolescent
pictomicrographs (postnatal day 35). The preliminary one-way ANOVA revealed a
significant effect of Litter, [F(9, 30) = 2.49, p =0.085], so the data underwent MML
analysis, and from the MML analysis, ICC was generated; r=0.453. So 45.3% of the
variability of distribution of data was attributed to the Litter variable. No significant
effect of Treatment was revealed (Table 4a) but a significant main, unpowered effect of
Sex emerged, [F(1, 13) =6.30, p =0.036] partial h2= 0.283, post-hoc power =0.73**
(Table 4b). The interaction of Treatment and Sex was not significant.

6.6.2 [125I] a-bungarotoxin (Table 3)
Medial Habenula: [125I] a-bungarotoxin binding was not evident in the Medial
Habenula.
Interpeduncular Nucleus: [125I] a-bungarotoxin binding was not evident in the
Interpeduncular Nucleus.
Raphe Nucleus: [125I] a-bungarotoxin binding was was visible only in the
adolescent pictomicrographs (postnatal day 35). The preliminary one-way ANOVA
revealed [F(9, 11)=2.08, p=0.135], so a MML analysis proceeded, and results of the
MML were used to calculate the ICC; r=0.214, or, Litter contributed 21.5% of the
variance associated with the distribution of the Luminance values. No significant effects
of Treatment (Figure 5a) or Sex (Figure 5b) or the interaction of Treatment and Sex were
revealed, and analysis ended.
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6.6.3 [125I] a-CtxMII (Table 3)
Medial Habenula: [125I]a-CtxMII binding was was visible only in the adolescent
pictomicrographs (postnatal day 35). The preliminary one-way ANOVA revealed a
significant effect of Litter, [F(9, 10) = 4.19, p = .018]; MML analysis proceeded.
Variance data from the MML analysis were used to compute the ICC; r=0.445. This
indicates that an estimated 44.5% of the variability of the Litter DV is attributed to the
Litter variable. No significant effects of Treatment or Sex (Tables 6a&b), or the
interaction of Treatment and Sex were significant, and analysis ended.
Interpeduncular Nucleus: [125I]a-CtxMII binding was not evident in the
Interpeduncular Nucleus.
Raphe Nucleus: : [125I]a-CtxMII binding was not evident in the Raphe Nucleus.

6.7 Cortices involved in motivated behavior or attention: Agranular Insular Cortex,
Auditory Cortex, Motor Cortex, Parietal Cortex, Somatosensory Cortex
6.7.1 [125I]-epibatidine (Table 3)
Agranular Insular Cortex: The preliminary one-way ANOVA revealed no
significant effect of Litter, [F(9, 30) = 0.092, p = 1.00]; this was followed by a betweensubjects factorial ANOVA. The ANOVA revealed no significant effects of Treatment
(Table 4a) or Sex (Table 4b), but Age was significant, [F(1, 31) =100.73, p =0.000]
partial h2= 0.759, post-hoc power =1.00 (Table 4c). Significant, but unpowered
interactions between Treatment × Sex [F(2, 31) =4.47, p =0.042] partial h2= 0.123, post-
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hoc power =0.501**; as well as between Sex × Age [F(2, 31) =4.49, p=0.042] partial h2=
0.123, post-hoc power =.501**. For this ligand, the neonates had greatest density labeling
in the deepest cortical layer. In the adolescent brain tissue, cortical layer III had the most
prominent epibatidine labeling.
Auditory Cortex: The preliminary one-way ANOVA revealed no significant effect
of Litter, [F(9, 30) =0.521, p =0.848], so the analysis proceeded with a between-subjects
factorial ANOVA. The ANOVA revealed a significant main effect of Treatment, [F(1,
31) = 7.144, p=0.012] partial h2= 0.183, post-hoc power =.82 (Table 4a; Figure 10), no
significant effect of Sex (Table b), but a significant main effect of Age, [F(1, 31) =55.62,
p=0.000] partial h2= 0.635, post-hoc power =1.00 (Table 4c). No interactions were
significant. For the neonates, density measurements were collected from a thin, but
intense, labeling in the deepest cortical layer. In the adolescent rats, the Auditory cortex
had the most intense binding apparent in cortical layers III and IV.
Motor Cortex: Densitometry measurements were not possible for [125I]epibatidine binding in the Motor Cortex.
Parietal Cortex: The preliminary one-way ANOVA revealed no significant effect
of Litter, F(9, 31)= 1.19, p=0.331], so the analysis continued with a between-subjects
factorial ANOVA. A significant Treatment effect was revealed, [F(1, 32) = 8.61,
p=0.006] partial h2= 0.212, post-hoc power =.88 (Table 4a; Figure 11). There were no
significant main effects of Sex (Table 4b) or Age (Table 4c), and no interactions. In the
neonatal rats, density measurements for this ligand were collected from the deepest
cortical layer of the Parietal cortex. In the adolescents, the labeling was intense for layers
I, III, V, and VI, with measurements taken from layers V and VI.
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Somatosensory Cortex: The preliminary one-way ANOVA revealed no significant
effects of Litter, F(9, 31)= 0.436, p=0.904], so the analysis proceeded with a betweensubjects factorial ANOVA. The ANOVA revealed a significant effect of Treatment, [F(1,
32) = 8.22, p=0.007] partial h2= 0.204, post-hoc power =.865 (Table 4a; Figure 12a), and
a significant but unpowered main effect of Sex, [F(1, 32) = 5.39 p=0.027] partial h2=
0.144, post-hoc power =.699** (Table 4b), as well as a significant main effect of Age
[F(1, 32) = 91.88, p=0.000] partial h2= 0.742, post-hoc power = 1.00 (Table 4c).
Treatment × Age was significant, [F(2, 32) = 11.54, p=0.002] partial h2= 0.215, post-hoc
power =.813 (Figure 12b). For the both neonatal and adolescent rats, cortical layers III,
IV and V were clearly labeled, with densitometry data collected from layer III.

6.7.2 [125I] a-bungarotoxin (Table 3)
Agranular Insular Cortex: The preliminary one-way ANOVA revealed no
significant effects of Litter, [F(9, 31) = 0.837, p = 0.589], so a between-subjects factorial
ANOVA revealed a significant Treatment effect, [F(1, 32) = 7.20, p = 0.011] partial %2=
184, post-hoc power = 0.82 (Table 5a; Figure 16), a significant, but unpowered, effect of
Sex [F(1, 32)=4.88, p=0.034] partial %2= 132, post-hoc power = 0.67** (Table 5b), as
well as a significant effect of Age [F(1, 32) = 52.85, p = 0.000] partial %2= 0.623, posthoc power = 1.00 (Tables 5c). No significant interactions were revealed. For this ligand,
the most rostral brain areas were used in the neonates, with data collected from intensely
labeled cortical layer III. For the adolescent group, layer III was also used, but
occasionally the best images were slightly more caudal; for those, IV and V were labeled
most intensly.
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Auditory Cortex: The preliminary one-way ANOVA revealed no significant effect
of Litter, [F(9, 29) = 0.480, p = 0.876], so the analyses proceeded with a betweensubjects factorial ANOVA. Significant effect of Treatment was found [F(1, 31) = 7.48, p
=0.10 ] partial h2= .194, post-hoc power = 0.833 (Table 5a; Figure 17), and no effect of
Sex (Table 5b), but a significant main effect of Age [F(1, 31) = 80.84, p =.000] partial
h2=723 , post-hoc power=1.00 (Table 5c). No significant interactions were revealed. For
both the neonatal and adolescent groups, cortical layer III was labeled most intensely and
used for densitometry data collection.
Motor Cortex: The preliminary one-way ANOVA revealed a significant effect of
Litter, [F(9, 30) = 1.87, p = 0.097], so a MML analysis was done; results of the MML
output were used to generate the ICC; r= 0.317. So, 31.7% of the variability in the
model can be explained by the random Litter variable. Treatment and Sex did not have
significant main effects (Tables 5a&b) or interactions, but Age did have a significant, but
unpowered, main effect [F(1, 30) = 12.59, p = 0.002] partial h2= 0.172, post-hoc power
= 0.776** (Table 5c). In the motor cortex, layer II was labeled most intensely and was
the darkest layer available for data collection.
Parietal Cortex: : No visible [125I] a-bungarotoxin binding was capable of
densitometry analysis.
Somatosensory Cortex: The preliminary one-way ANOVA revealed a significant
effect of Litter, [F(9, 30) = 2.13, p = 0.059], so the analysis proceeded using MML. The
results of the MML analysis were used to calculate ICC; r= 0.413, meaning the Litter
variable contributes 41.3% of the variance in the Luminance DV. The MML analysis
revealed no significant main effects of Treatment or Sex (Tables 5a&b), but a main effect
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of Age, [F(1, 31) = 14.36, p=0.001] partial h2= 0.188, post-hoc power =0.83 (Table 5c).
No interactions achieved statistical significance. For the neonatal group, cortical layers I,
III and IV were labeled clearly; for both the neonatal and adolescent group, cortical layer
V was selected for data collection, because of the intensity of ligand binding.
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Table 3.1a [ I]epibatidine binding. Luminance values and relative optical density
(means/±S.E.M.) in offspring exposed to prenatal nicotine (0.05 mg/kg/day) or saline.
Results are collapsed across age and sex. Significant p-values reflect between-subjections
comparisons; an asterisk * indicates a significant group difference with statistical power
≥ 0.80.

LUMINANCE
Region

PN

ROD
PS

PN

PS

Sig.

Auditory
Cortex

191.95±4.37

183.00±3.12 0.1248±0.0010

0.1455±0.0074

p=0.012*

BLA

190.80±2.14

182.19±2.44 0.1270±0.0038

0.1467±0.0060

p=0.016

Cingulate
Cortex

169.36±2.66

176.69±3.12 0.1788±0.0069

0.1603±0.0074

p=0.009*

Dorsal
Striatum

185.68±1.83

179.06±1.89 0.1388±0.0047

0.1553±0.0049

p=0.007*

Frontal Cortex

181.11±3.11

182.02±3.73 0.1495±0.0073

0.1482±0.0091

p=0.605

Insular Cortex

184.50±3.51

184.88±4.23 0.1410±0.0086

0.1405±0.0098

p=0.894

IPN

86.32±1.34

84.58±2.11

0.4859±0.0039

0.4865±0.0037

p=0.481

MHb

81.98±1.65

77.40±1.65

0.5236±0.0043

0.5601±0.0043

p=0.036

NAcc

175.01±2.61

185.79±2.15 0.1649±00.67

0.1395±0.0040

p=0.001*

Parietal Cortex

208.41±1.62

201.66±1.61 0.8832±0.0043

0.1028±0.0042

p=0.006*

PPTg

176.12±2.41

173.48±3.01 0.1617±0.0060

0.1683±0.0070

p=0.200

Raphe Nucleus

188.77±6.39

170.49±6.01 0.1314±0.0112

0.1754±0.0099

p=0.115

Somatosensory
Cortex

198.07±4.50

188.97±2.68 0.1104±0.103

0.1314±0.0063

p=0.007*

Substantia
Nigra
VTA

127.05±2.65

122.09±2.99 0.3085±0.0063

0.3200±0.0070

p=0.176

121.13±1.98

129.17±1.72 0.3299±0.0047

0.3009±0.0044

p=0.007*
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Table 3.1b [ I]epibatidine binding. Luminance values and relative optical density
(means/±S.E.M.) in male and female brain regions. Results are collapsed across age, and
prenatal nicotine (0.05 mg/kg/day) or saline exposure during gestational days 8-21.
Significant p-values reflect between-subjections comparisons; an asterisk * indicates a
significant group difference with statistical power ≥ 0.80.

LUMINANCE
Region

Auditory Cortex

M

ROD
F

M

189.92±3.22
Auditory186.70±4.41
Cortex

F

Sig.

BLA

186.86±2.55

186.12±2.44

0.1287±0.
0076
0.1389±0.0068

Cingulate Cortex

170.22±2.27

175.83±3.5

0.1799±0.0059

0.1619±0.0085

p=0.042

Dorsal Striatum

183.69±2.55

186.12±2.45

0.1436±0.0067

0.1375±0.0061

p=0.659

Frontal Cortex

177.05±2.14

186.33±3.85

0.1608±0.0040

0.1379±0.0084

p=0.004*

Insular Cortex

182.69±3.22

186.70±4.41

0.1456±0.0057

0.1380±0.102

p=0.159

IPN

86.03±2.05

84.87±1.44

0.4752±0.0053

0.4865±0.0048

p=0.635

MHb

78.59±1.76

80.78±1.67

0.5350±0.0045

0.5297±0.0043

p=0.303

NAcc

182.40±2.32

178.41±2.94

0.1464±0.0060

0.1561±0.0070

p=0.196

Parietal Cortex

206.30±2.01

203.76±1.48

0.0930±0.0036

0.0982±0.0037

p=0.279

PPTg

175.82±3.00

173.92±5.92

0.1620±0.0069

0.1676±0.0110

p=0.547

Raphe Nucleus

187.11±6.93

172.13±5.92

0.1354±0.0120

0.1722±0.0118

p=0.036

Somatosensory
Cortex
Substantia Nigra
VTA

196.9±3.95

190.15±3.59

0.1265±0.0089

0.1281±0.0084

p=0.019

125.81±3.05
126.96±2.30

123.39±1.80
123.03±1.68

0.3128±0.0072
0.3078±0.0061

0.3231±0.0050
0.3313±0.0043

p=0.511
p=0.176
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0.1361±0.0102

p=0.153

0.1372±.0062

p=0.733
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Table 3.1c [ I]epibatidine binding. Luminance and elative optical density
(means/±S.E.M.) in neonatal and adolescent rat brain regions. Results are collapsed
across sex, and prenatal nicotine (0.05 mg/kg/day) or saline exposure during gestational
days 8-21. Significant p-values reflect between-subjections comparisons; an asterisk *
indicates a significant group difference with statistical power ≥ 0.80.
LUMINANCE
Region

ROD

Neonate

Adol.

Neonate

Adol.

Auditory
Cortex

199.95±3.06

175.00±2.08

0.1064±0.0070

0.1639±0.0054

p=0.000*

BLA

187.94±2.24

185.04±2.69

0.1332±0.0057

0.1401±.0065

p=0.398

Cingulate
Cortex

181.62±2.74

164.43±1.71

0.1485±0.0064

0.1912±0.0042

p=0.000*

Dorsal
Striatum

200.60±1.89

163.35±1.97

0.1056±0.0040

0.1945±0.0046

p=0.000*

Frontal
Cortex

191.16±2.72

171.48±1.75

0.1260±0.0067

0.1732±0.0044

p=0.000*

Insular
Cortex

198.67±2.57

170.71±1.76

0.1092±0.0056

0.1754±0045

p=0.000*

IPN

85.36±1.79

85.54±1.75

0.4910±0.0046

0.4881±0.0044

p=0.914

MHb

77.56±1.70

81.82±1.63

0.5401±0.0043

0.5186±0.0040

p=0.050

NAcc

182.10±2.15

178.17±3.08

0.1469±0.0039

0.1569±0.0071

p=0.271

Parietal
Cortex

205.78±1.72

204.28±1.84

0.0938±0.0044

0.0963±0.0047

p=0.519

PPTg

166.05±1.95

182.81±1.79

0.1878±0.0045

0.1471±0.0046

p=0.000*

Raphe
Nucleus

187.11±6.93

172.13±5.92

0.1363±0.0102

0.1718±0.0105

p=0.036

SSC

206.38±2.95

180.66±1.89

0.0926±0.0068

0.1505±0.0049

p=0.000*

Substantia
Nigra

122.99±2.95

126.19±2.74

0.3200±0.0068

0.3084±0.0064

p=0.382

VTA

123.99±1.89

126.06±2.21

0.3147±0.0049

0.3081±0.0057

p=0.949

70

Sig.
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Table 3.2a [ I]bungarotoxin binding. Luminance and relative optical density
(means/±S.E.M.) in brain regions of offspring exposed to nicotine (0.05 mg/kg/day) or
saline during gestational days 8-21. Results are collapsed across sex and age. Significant
p-values reflect between-subjections comparisons; an asterisk * indicates a significant
group difference with statistical power ≥ 0.80.

LUMINANCE

ROD

Region

PN

PS

PN

Auditory Cortex

175.61±2.66

182.09±2.99

0.1632±0.0069

0.1472±0.0070

p=0.010*

BLA

142.09±1.47

142.61±1.33

0.2584±0.0049

0.2633±0.0038

p=0.773

Cingulate
Cortex

167.89±1.61

174.19±2.08

0.1827±0.0042

0.1671±0.0054

p=0.011*

Dorsal Striatum

231.00±4.31

225.74±4.85

0.0421±0.0101

0.0534±0.0105

p=0.447

Insular Cortex

175.09±2.46

181.31±2.69

0.1660±0.0062

0.1511±0.0064

p=0.011*

Hippocampus

100.74±1.94

112.86±2.75

0.4107±0.0045

0.3577±0.0066

p=0.004*

Motor Cortex

179.89±1.79

178.51±1.74

0.1525±0.0047

0.1556±0.0045

p=0.680

NAcc

169.95±1.85

162.20±1.87

0.1772±0.0047

0.1992±0.0047

p=0.010*

PPTg

153.91±2.10

155.12±2.79

0.2211±0.0055

0.2194±0.0067

p=0.720

Raphe Nucleus

150.47±1.39

146.74±3.31

0.2364±0.0040

0.2404±0.0077

p=0.408

Somatosensory
Cortex

170.96±1.88

175.73±2.49

0.1745±0.0048

0.1624±0.0061

p=0.271

Substantia Nigra

118.23±3.27

123.66±3.44

0.3365±0.0058

0.3215±0.0065

p=0.290

71

PS

Sig.
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Table 3.2b [ I]bungarotoxin binding. Luminance and relative optical density
(means/±S.E.M.) in male and female brain regions. Results are collapsed across age, and
prenatal nicotine (0.05 mg/kg/day) or saline exposure during gestational days 8-21.
Significant p-values reflect between-subjections comparisons; an asterisk * indicates a
significant group difference with statistical power ≥ 0.80.
LUMINANCE
Region

ROD

Male

Female

Male

Auditory
Cortex

178.04±3.02

179.53±2.79

0.1575±0.0071

0.1531±0.0067

p=0.571

BLA

139.8±0.98

144.91±1.51 0.2742±0.0020

0.2474±0.0038

p=0.007*

Cingulate
Cortex

175.64±2.38

172.37±2.18 0.1641±0.0044

0.1711±0.0057

p=0.244

Dorsal
Striatum

226.46±5.25

230.24±3.91 0.0518±0.0150

0.0456±0.0088

p=0.378

Insular Cortex

175.64±2.38

180.76±2.82

0.1649±0.0058

0.1522±0.0068

p=0.034

Hippocampus

108.88±3.22

104.74±2.08 0.3736±0.0076

0.3945±0.0054

p=0.143

Motor Cortex

177.67±1.65

180.73±1.82 0.1588±0.0045

0.1504±0.0046

p=0.123

NAc

164.13±1.66

168.02±2.18 0.1920±0.0046

0.1817±0.0057

p=0.097

PPTg

154.10±2.47

154.83±2.42 0.2194±0.0062

0.2173±0.0061

p=0.950

Raphe Nucleus

150.76±1.56

146.44±3.19 0.2309±0.0045

0.2421±0.0075

p=0.147

Somatosensory
Cortex

174.12±2.38

172.58±2.16 0.1675±0.0044

0.1706±0.0041

p=0.525

Substantia
Nigra

121.21±3.47

120.44±3.47 0.3395±0.0081

0.3292±0.0081

p=0.651

72

Female

Sig.
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Table 3.2c [ I]bungarotoxin binding. Luminance and relative optical density
(means/±S.E.M.) in neonatal and adolescent rat brain regions. Results are collapsed
across sex, and prenatal nicotine (0.05 mg/kg/day) or saline exposure during gestational
days 8-21. Significant p-values reflect between-subjections comparisons; an asterisk *
indicates a significant group difference with statistical power ≥ 0.80.

LUMINANCE
Region

ROD

Neonatal

Adol.

Neonatal

Adol.

Auditory Cortex

168.21±1.78

188.79±1.57

0.1814±0.0046

0.1325±0.0045

p=0.000*

BLA

141.65±1.45

143.06±1.33

0.2653±0.0048

0.2599±0.0039

p=0.434

Cingulate Cortex

186.63±2.16

169.78±1.47

0.1378±0.0050

0.1796±0.0036

p=0.002*

Insular Cortex

186.63±2.16

169.78±1.47

0.1382±0.0050

0.1789±0.0036

p=0.000*

Hippocampus

111.68±1.67

101.94±3.15

0.3614±0.0046

0.4050±0.0075

p=0.000*

Motor Cortex

175.80±1.73

182.60±1.44

0.1652±0.0040

0.1479±0.0048

p=0.002*

NAc

167.81±2.08

164.33±1.81

0.1852±0.0054

0.1916±0.0047

p=0.136

Somatosensory
Cortex

168.82±1.83

1177.88±2.21

0.1823±0.0048

0.1578±0.0051

p=0.001*

73

Sig.
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Table 3.3a [ I]conotoxin MII binding. Luminance and relative optical density
(means/±S.E.M.) in brain regions of offspring exposed to nicotine (0.05 mg/kg/day) or
saline during gestational days 8-21. Results are collapsed across sex and age. Significant
p-values reflect between-subjections comparisons; an asterisk * indicates a significant
group difference with statistical power ≥ 0.80.

LUMINANCE
Region

ROD

PN

PS

PN

PS

Sig.

Dorsal Striatum

220.71±1.40

220.94±0.921

0.0645±0.0047

0.0629±0.0020

p=0.777

MHb

177.66±3.76

191.24±3.32

0.1580±0.0082

0.1254±0.0077

p=0.064

NAc

217.37±2.88

216.52±1.70

0.07045±0.0066

0.0709±0.0043

p=0.656

Substantia Nigra

184.64±3.70

181.78±4.53

0.1415±0.0084

0.1483±0.0099

p=0.925

VTA

204.50±1.87

206.30±2.88

0.1000±0.0049

0.0920±0.0082

p=0.020

74
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Table 3.3b [ I]conotoxin MII binding. Luminance and relative optical density
(means/±S.E.M.) in male and female brain regions. Results are collapsed across age, and
prenatal nicotine (0.05 mg/kg/day) or saline exposure during gestational days 8-21.
Significant p-values reflect between-subjections comparisons; an asterisk * indicates a
significant group difference with statistical power ≥ 0.80.
LUMINANCE
Region

ROD

Male

Female

Dorsal
Striatum

218.94±1.12

222.91±0.84

MHb

184.24±2.78

184.65±5.25

NAcc

215.05±2.45

Substantia
Nigra
VTA

Male

Female

0.0676±0.0039

Sig.

0.0592±0.0018

p=0.019*

0.1420±0.0065

0.1409±0.0112

p=0.919

219.34±0.68

0.0745±0.0062

0.0651±0.0010

p=0.203

184.64±3.70

181.78±4.53

0.1418±0.0084

0.1475±0.0109

p=0.925

204.50±1.87

206.30±2.88

0.0967±0.0045

0.0932±0.0069

p=0.214
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Table 3.3c [ I]conotoxin MII binding. Luminance values and relative optical density
(means/±S.E.M.) in neonatal and adolescent rat brain regions. Results are collapsed
across sex, and prenatal nicotine (0.05 mg/kg/day) or saline exposure during gestational
days 8-21. Significant p-values reflect between-subjections comparisons; an asterisk *
indicates a significant group difference with statistical power ≥ 0.80.

LUMINANCE

ROD

Region

Neonates

Adol.

Neonates

Adol.

Substantia Nigra

199.46±1.76

171.04±1.82

0.1069±0.0045

0.1762±0.0047

75

Sig.
p=0.000*

Figure 3a.
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Figure 3.1 Dam and offspring weight gain. (A) Mean weight gain (±SEM) of dams (in
grams), presented by maternal treatment group. Daily weights were recorded for
pregnant dams, gestational days 0-21; graphs represent grams of gained weight on
gestational days 0, 7, 14 and 21. A Mixed Models ANOVA with Repeated
Measures revealed that gestational treatment had no significant effect on weight
gain. (B) Mean weight gain (± SEM) of offspring (in grams), presented by
prenatal treatment. Weight gain for postnatal days 1, 7, 14, and 21 are
represented. A Mixed Models ANOVA with Repeated measures found no
significant main effect of prenatal treatment on weight gain.
Figure 4
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Figure 3.2 Number of male and female offspring produced. The mean number
(±SEM) of male (left), female (middle), and total (right) offspring delivered by
dams in each Treatment group. ANOVAs revealed no differences between
number of pups born to each group, and Chi-Square test showed no difference in
the ratio of males to females born.
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Figure 5a.
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Figure 3.3 Latency for righting reflex and negative geotaxis. (A) Mean latency
(±SEM) (in seconds) for PN and PS offspring on Righting Reflex task, as
measured across three consecutive days (postnatal days 3-5) during the neonatal
period. A Mixed Models ANOVA with Repeated Measures revealed that prenatal
treatment had no significant effect on Righting Reflex latency. (B) Mean latency
(±SEM) (in seconds) for PN and PS offspring on Negative Geotaxis task, as
measured across three consecutive days (postnatal days 8-10) during the neonatal
period. A Mixed Models ANOVA with Repeated Measures revealed that prenatal
treatment had no significant effect on Negative Geotaxis latency.

Figure 6

Ventral Tegmental Area~ α4β2 nAChRs
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Figure 3.4 Treatment effect: a4b2 nAChRs in VTA. Mean Luminance (±SEM) value
for [125I]-epibatidine binding in the Ventral Tegmental Area. A 2 × 2 ×2
Univariate ANOVA revealed a significant main effect of Treatment [F(1,
31)=8.40, p=0.007, partial ƞ2=0.213, post-hoc power=0.89. PN M=121.13±1.98;
PS M=129.17±1.72.
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Figure 7

Nucleus Accumbens~ α4β2 nAChRs
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Figure 8

Dorsal Striatum ~ α4β2 nAChRs
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Figure 3.5 Treatment effect: a4b2 nAChRs in NAcc. Mean Luminance (±SEM) values
for [125I]-epibatidine binding in the NAcc. MML analysis found a significant fixed
effect of Treatment, [Fixed Effect (1, 32) = 12.71, p = 0.001, ƞ2 =0.194, power =
0.85. PN M=175.01±2.61; PS M=185.79±2.15.
Figure 3.6 Treatment effect: a4b2 nAChRs in Dorsal Striatum. Mean Luminance
(±SEM) values for [125I]-epibatidine binding in the Dorsal Striatum. A 2 × 2 ×2
Univariate ANOVA revealed a significant main effect of Treatment [F(1,
31)=8.41, p=0.007, partial ƞ2=0.213, post-hoc power=0.88. PN M=185.68±1.83;
PS M=179.06±1.89.
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Figure 9

Cingulate Cortex ~ α4β2 nAChRs
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Figure 10

Auditory Cortex~ α4β2 nAChRs
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Figure 3.7 Treatment effect: a4b2 nAChRs in Cingulate Cortex. Mean Luminance
(±SEM) values for [125I]-epibatidine binding in the Cingulate Cortex. A 2 × 2 ×2
Univariate ANOVA revealed a significant main effect of Treatment [F(1,
32)=7.68, p=0.009, partial ƞ2=0.194, post-hoc power=0.85. PN M=169.36±2.66;
PS M=176.69±3.12.
Figure 3.8 Treatment effect: a4b2 nAChRs in Auditory Cortex. Mean Luminance
(±SEM) values for [125I]-epibatidine binding in the Auditory Cortex. A 2 × 2 ×2
Univariate ANOVA revealed a significant main effect of Treatment [F(1,
32)=7.14, p=0.012, partial ƞ2=0.183, post-hoc power=0.82. PN M=191.95±4.37;
PS M=183.00±3.12.
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Figure 11

Parietal Cortex α4β2 nAChRs
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Figure 12a.

Somatosensory Cortex ~ α4β2 nAChRs
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Figure 3.9 Treatment effect: a4b2 nAChRs in Parietal Cortex. Luminance (±SEM)
values for [125I]-epibatidine binding in the Parietal Cortex. A 2 × 2 ×2 Univariate
ANOVA revealed a significant main effect of Treatment [F(1, 32)=8.61, p=0.006,
partial ƞ2=0.212, post-hoc power=0.88. PN M=208.41±1.62; PS M=201.66±1.61.
Figure 3.10 Treatment effect: a4b2 nAChRs in Somatosensory Cortex. Luminance
(±SEM) values for [125I]-epibatidine binding in the Somatosensory Cortex. A 2 ×
2 ×2 Univariate ANOVA revealed a significant main effect of Treatment [F(1,
32)=11.19, p=0.002, partial ƞ2=0.259, post-hoc power=0.95. PN M=198.07±4.5;
PS M=188.97±2.68.
Figure 12b.
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Figure 3.11 Treatment X Age interaction: Somatosensory Cortex. Luminance
(±SEM) values for [125I]-epibatidine binding in the Somatosensory Cortex. The
ANOVA revealed a significant interaction between Treatment × Age, [F(1,
32)=8.37, p=0.007, partial ƞ2=0.206, post-hoc power=0.95. PN neonates:
M=213.84±2.68; PS neonates: M=197.13±2.77; PN adolescents: M=180.50±2.18,
PS adolescents: M=181.81±2.65. The PN neonates had fewer receptors early in
life, compared to the PS group; both PN and PS subjects significantly increased
receptor density to similar levels by adolescence.
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Figure 13
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Figure 14

Hippocampus ~ α7 nAChRs
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Figure 3.12 Treatment Effect: a7 nAChRs in Nucleus Accumbens Luminance
(±SEM) values for [125I]a-bungarotoxin binding in the NAcc. MML analysis
found a significant fixed effect of Treatment, [Fixed Effect (1, 32) = 7.59, p =
0.010, ƞ2 =0.192, power = 0.83. PN M=162.95±1.85; PS M=169.20±1.89.
Figure 3.13 Treatment Effect: a7 nAChRs in Hippocampus. Luminance (±SEM)
values for [125I]a-bungarotoxin binding in the Hippocampus. MML Analysis
revealed a significant main effect of Treatment, [Fixed Effect (1, 32) = 17.89, p =
0.000, ƞ2 =0.229, power = 0.91. PN M=100.74±1.94; PS M=112.86±2.75.
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Figure 15

Cingulate Cortex ~ α7 nAChRs
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Figure 16

Agranular Insular Cortex ~ α7 nAChRs
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Figure 3.14 Treatment Effect: a7 nAChRs in Cingulate Cortex. Luminance (±SEM)
values for [125I]a-bungarotoxin binding in the Cingulate Cortex. A 2 × 2 ×2
Univariate ANOVA revealed a significant main effect of Treatment, [F(1, 32) =
7.27, p = 0.011] partial %2= 185, post-hoc power = 0.82. PN M=167.88±1.61; PS
M=174.19±2.08.
Figure 3.15 Treatment Effect: a7 nAChRs in Insular Cortex. Luminance (±SEM)
values for [125I]a-bungarotoxin binding in the Agranular Insular Cortex. A 2 × 2
×2 Univariate ANOVA revealed a significant main effect of Treatment, [F(1, 32)
= 7.19, p = 0.011] partial %2= 184, post-hoc power = 0.82. PN M=175.09±2.46;
PS M=181.31±2.69Figure 17. Luminance (±SEM) values for [125I]a-bungarotoxin
binding in the Auditory Cortex. A 2 × 2 ×2 Univariate ANOVA revealed a
significant main effect of Treatment, [F(1, 31) = 7.48, p = 0.010] partial %2= 194,
post-hoc power = 0.83. PN M=175.61±2.66; PS M=182.09±2.99.

Figure 17

Auditory Cortex ~ α7 nAChRs
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Figure 3.16 Treatment Effect: a7 nAChRs in Auditory Cortex. Luminance (±SEM)
values for [125I]a-bungarotoxin binding in the Auditory Cortex. A 2 × 2 ×2
Univariate ANOVA revealed a significant main effect of Treatment, [F(1, 31) =
7.48, p = 0.010] partial %2= 194, post-hoc power = 0.83. PN M=175.61±2.66; PS
M=182.09±2.99.
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CHAPTER IV
CONCLUSIONS
Low-dose IV prenatal nicotine administration during gestational days 8-21
resulted in quantifiable changes in nicotinic receptor expression in brain regions
underlying motivated behavior and attention processing. Autoradiography and
densitometry revealed significant, sufficiently powered differences between PN and PS
treatment groups in α4β2 nAChR expression levels in the VTA and NAc.
As hypothesized (Hypothesis 1, section 4.3), PN subjects had greater α4β2
nAChR density in the VTA and NAcc. No differences in α4β2 nAChR receptor density
were found in the PFC as a function of Treatment.
As hypothesized (1) PN subjects had fewer α7-containting nAChRs in the NAc
However, the opposite was found in the Hippocampus; a greater density of α7containting nAChRs found in the Hippocampus for PN animals (no differences were
found for the VTA or PFC). As hypothesized, nAChR expression levels following
prenatal nicotine were also altered as a function of age (2).
nAChR expression density increased between postnatal day 10 and postnatal day
35, as hypothesized (2), in the PFC (α4β2) and Hippocampus (α7). However, in the
PPTg, α4β2 expression decreased with age. No age differences were found in the
hypothesized brain regions of VTA or NAc. Sex differences in nAChR expression levels
were found in the PFC; males had greater density of α4β2 nAChRs, as hypothesized (3),
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but no other differences between males and females were found, within any hypothesized
brain regions.
Collectively, these results support the hypothesis that prenatal nicotine exposure
changes nicotinic receptor expression in brain areas engaged during reward-seeking
behavior and attention processing.
More research is needed to validate and expand upon these findings. The current
set of experiments had methodological and design limitations, discussed below. Several
other brain areas implicated in reward-seeking behavior, known to be altered by prenatal
nicotine, and expressing α4β2, α7-containing, and α6-containing nAChRs, were analyzed
for receptor density—those findings are discussed later in the conclusions section.

7.1 Litter Parameters

The use of IV PN resulted in a lack of growth related deficits, as reported in
previous published reports from this laboratory (Harrod et al., 2011; Lacy et al., 2011;
Harrod et al., 2012; Lacy et al., 2012; Morgan et al., 2013; Lacy et al., 2014; Lacy et al.,
2016). Clinical research has consistently reported low birth weight following gestational
tobacco exposure (via maternal smoking), and this reduced weight has historically
confounded clinical findings of altered neurodevelopmental capacity throughout the
lifespan (Comstock et al., 1971; Fried & O’Connell, 1987; Meyer & Comstock, 1972;
Simpson 1957).
Preclinical research is rife with similar outcomes; reduced birth weight is often
reported across several gestational nicotine administration routes (Becker & Martin,
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1971; Slotkin 2004; Schneider 2010); however, birth weight differences between prenatal
treatment groups become nonsignificant about a month after parturition (Levin et al.,
2006).
The findings reported here cannot be attributed to any nutritional deficits; during
gestation, no differences in dam weight gain as a function of gestational treatment. After
parturition, no significant differences in weight gain between PN and PS offspring
appeared through the first three weeks of life.
In addition to lower birth weight, fetal ischemia/hypoxia is a cited source of
abnormal developmental trajectories. For example, the pharmacokinetic distribution of
nicotine administered through the OMP method results in much less nicotine entering the
brain, compared to the amount released from the OMP continuously.
Because much of the drug is metabolized before reaching target sites, many
published experiments use a daily dose of nicotine around 2.4 mg/kg/day (Birnbaum et
al., 1994). This dose is about 15x higher than the dose used for this experiment
(0.05mg/kg/injection, which is 100% bioavailable upon injection). The higher doses of
nicotine prenatally administered (via OMP) result in a 40% reduction of uterine and
placental blood flow.
Low-dose IV prenatal nicotine administration does not produce confounds of
restricted intrauterine growth or low birth weight, and the ontogenetic measurements of
postnatal development (litter size/composition, reflexes, and eye opening) were not
disrupted by low-dose IV nicotine exposure on GD 8-21.

The remainder of the Conclusions section is organized to review
results specific to the hypotheses (Section 4.3.1), followed by information

93

about experimental limitations. A brief summary of non-hypothesized
experimental results follows the limitations section.

7.2 Mesocorticolimbic DA pathway: VTA, NAc, PFC

A hypothesized increase in a4b2 nAChR expression levels in the MCL DA
reward neurocircuitry was partially confirmed by statistically significant increases in
receptor density in the VTA and NAc as a function of Treatment (hypothesis 1). This is
supported by similar research by Tizabi et al., (1997) using the OMP route of
administration for nicotine.
This finding is also supported by evidence for the capacity of nicotinic receptors
to upregulate. Although the fetal compartment is unique, chronic adult nicotine exposure
during tobacco dependence causes prolonged nAChR desensitization, this deep
desensitization causes an upregulation in nAChR receptor number (Dani & Heinemann,
1996; Fenster et al., 1999). This upregulation is the result of homeostatic regulation.
Because offspring were exposed to chronic nicotine during gestational days 8-21, the
NAc and VTA may have upregulated a4b2 nAChRs in these regions.
The a4b2 nAChR in particular is critical for addiction to nicotine, and induces
firing of dopamine neurons in the VTA following stimulation (Pons et al., 2008). An
upregulation of expression for this receptor subtype in the VTA and NAc fits well with
the clinical literature, which shows higher rates of nicotine dependence and early
initiation of tobacco smoking behaviors following PCSE (Buka et al., 2003; Kandel et al.,
1994; Brennan et al., 2002; O’Callaghan et al., 2006; Goldschmidt et al., 2012).
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The NAc had fewer a7 nAChRs expressed as a function of Treatment (hypothesis
1). This reduced expression was hypothesized (1) to extend to VTA, PFC, Hippocamous
and PPTg. Tizabi et al., (2000) reported reduced expression of the a7 nAChR following
prenatal nicotine exposure.
The a7 nAChR subtype is critical during gestation, and is responsible for the
development of the DA reward neurocircuitry. During GD13, the a7 nAChR guides the
newly-generated DA neuron to the DA receptor for the first time during gestation,
establishing the earliest structure of the DA neurocircuitry (Dwyer et al., 2008).
The reduced a7 nAChR expression in the NAc, which projects to the PFC, could
underlie reduced dopamine firing in this region following PN exposure. PN exposure
changes the development of catecholamine neurons in the VTA and substantia nigra
(Slotkin et al., 1987a; Navarro et al., 1988; Ribary & Lichtensteiger, 1989; Kane et al.,
2004; Chen et al., 2005; Franke et al., 2008); and results in decreased DA content and D2
receptors in the NAc and striatum on postnatal day 22 (Richardson & Tizabi, 1994). a7
nAChRs are located on and act on DA neurons in the NAc and Striatum, so the reduced
DA content in these regions may be reflected by lower a7 nAChR levels.
No other hypothesized brain regions showed reduced a7 nAChR expression
levels, and the hypothesis was only confirmed for one brain area (see Limitations
section).
Males had significantly greater a4b2 nAChR expression in the PFC than females,
which is consistent with published literature (Tizabi et al., 1997) and confirms the
hypothesis (3) of higher nAChR levels in Males following PN exposure. Males are also
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more likely to experience problems with conduct disorder and ADHD, following prenatal
tobacco smoke exposure.
The dysregulation of attention processing and impulse regulation in this
population may be a function of cholinergic receptor changes, as the α4β2 nAChR to
regulates multiple attentional processes (cue detection, divided attention, and sustained
attention; Turchi & Sarter, 1997). nAChRs in the PFC also regulate behavior related to
emotional reactivity—inhibiting inappropriate emotions, impulses, and habits (Miller,
2000).
Receptor expression levels were not a function of Sex for any other hypothesized
brain regions (see Limitations, below), and the hypothesis was not confirmed.
Age was a significant main effect for α4β2 nAChR expression in the PFC, with
higher expression levels found in the adolescent group. This is consistent with the
hypothesis (2) predicting greater density of all five hypothesized brain regions. Tizabi et
al., (1997; 2000) reported significantly higher nAChR levels in brains of adolescent rats
(PND36-38) following OMP prenatal exposure. A significant effect of Age was not
revealed in VTA or NAc.
A lack of significant treatment, sex, or age effects are possibly attributable to the
experimental Limitations (see below).

7.3 Hippocampus and PPTg

A significant Treatment effect was found for α7 nAChR expression levels in the
Hippocampus, with PN-exposed offspring expressing higher levels of nAChRs in the
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Hippocampus. This finding is the opposite of the hypothesized results (hypothesis 1,
reduced α7 nAChR expression). However, upregulation of the α7 nAChR as a function of
Treatment may contribute to impaired memory function in prenatal-nicotine exposed
offspring.
Hippocampal α7 nAChRs are active during memory processes. Several studies
report reduced acquisition of memory tasks following PN exposure (Sorenson et al. 1991;
Li et al., 2014).
In the PPTg, the only main effect revealed was Age, for α4β2 nAChR expression.
Higher nAChR levels were found in neonates, with lower levels in adolescents. This
could be attributed to the widely-reported expression pattern typical of nAChRs; α6, α7
and α4β2 nAChRs first appear during the second gestational trimester, then expression
levels climb steadily, to peak by PND 21, followed by a decline to levels maintained
through adulthood (Azam et al., 2007; Pugh & Berg, 1994; Small et al., 1995; Xiang et
al., 1998). Treatment and Sex did not emerge as significant main effects in the PPTg.

7.4 Limitations

Limitations of the experiments reported here include 3 possible sources of
variability in data analysis. (1) Experimental design: with 10 dams contributing 4
offspring each, the statistical power was not present to conclude multiple significant
group differences were not spurious.
The MML analysis, used when Litter was shown to have an undue effect on the
variability of data analysis, often violated the multilevel modeling assumption of
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convergence. This was likely because the sample size requirement wasn’t met for robust
multilevel modeling. Future research with higher sample size would undoubtedly find
statistically significant, sufficiently powered differences in receptor expression for many
brain regions, as a function of Treatment.
(2) Tissue slicing/preparation: a proportion of tissue, approximately a third of
tissue images submitted for densitometry, were torn, with the ventral half of the slice
missing, or with holes in the slice. Perhaps uneven tissue slicing resulted in the loss of
tissue. Within the [125I]-bungarotoxin dataset, for example, the tissue was too damaged
(in both age groups), that there were not enough intact Frontal Cortex images intact for
densitometry.
Damage of tissue negatively affected densitometry analysis in many brain areas,
identified in the results section with the statement “binding was not capable of
densitometry analysis.” For sections in which the nAChR was not expressed, the
statement “binding was not evident” is used.
(3) Autoradiography: The images obtained following autoradiography and ligand
binding were damaged, in many cases, beyond what could be expected from tissue slicing
errors. One culprit may be the age of the tissue at the time of radioligand binding, with
neonatal tissue being prone to damage which can occur with application of harsh
radioactive isotopes. Many slices appeared as though a third or more of the slice had been
disintegrated.
Additionally, the tissue images retained for densitometry following [125I]
Conotoxin MII (binding a6-containing nAChRs) binding were limited to the areas of a6-
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containing nAChR expression (namely, midbrain dopamine neurons); Beyond this
limitation, there were very few slice images available for the neonatal age group.
Of the n=17 neonatal subjects with images of bound tissue, an average of 13
images of single slices were available (per subject) for densitometry analysis. The
adolescent group had twice as many slice images available for densitometry analysis to
collect luminance values, but this still resulted in a limited number of options to obtain
the 4 images with the brain region of interest available and intact for densitometry.

7.5 Summary of Brain Regions Analyzed

7.5.1 Substantia Nigra and Dorsal Striatum
The Substantia Nigra (SN) and Dorsal Striatum (DS) were selected for
Densitometry analysis shortly after formal hypothesis testing began. The SN is another
hub (along with the VTA) of dopamine cell bodies; SN dopamine neurons project to the
DS. The only significant differences in Substantia Nigra expression found was a function
of Age; Adolescent rat brains expressed a greater density of a6 nAChRs, compared to
neonates (across Treatment and Sex).
Density of α4β2 nAChRs in DS (which receives projections from SN) were
significantly higher for the PS Treatment group, compared to the PN-exposed offspring.
This region also had increased α4β2 nAChR density in adolescence, compared to the
neonatal group.
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7.5.2 BLA & Cingulate Cortex

The Anterior Cingulate Cortex (CC) is recognized in clinical literature,
characterized by reduced activation during cognitive processing for drug-addicted
subjects (Goldstein et al., 2009). Because of its involvement in attention processing and
drug addiction, the CC was analyzed for nAChR receptor densitometry.
α4β2 nAChR expression pattern variability was significantly different as a
function of Treatment, with PN offspring expressing significantly greater density of α4β2
nAChRs in the CC, compared to PS offspring. For both α4β2 and α7 nAChRs, the CC
offspring had greater receptor density binding in adolescence, compared to the neonatal
group.
The BLA is functionally connected with the Hippocampus, as a part of
neurocircuitry underlying the emotional processing of stimuli, emotional memory, and
learning, (Pidoplichko et al, 2013; Subramaniyan & Dani, 2015). Acquisition of
stimulant-seeking behavior is regulated by efferents sent from the BLA to the NAc, and
lesions of the BLA prevent the acquisition of drug-seeking behavior (Whitelaw et al.
1996). Activation of both α7 and α4β2 nAChRs in the BLA are a function of rewardbased learning and seeking behavior.
This study found one significant difference in the BLA; Males expressed greater
density of the α7 nAChR, compared to females.

100

7.5.3 Medial Habenula, Interpeduncular Nucleus, Raphe Nucleus

The Medial Habenula (MHb) was examined for nAChR densitometry, as it is
often-cited for its involvement in tobacco smoking dependence (Kenny et al., 2012);
although the MHb is commonly associated with the α5 containing nAChR subunits, both
α4β2 and α6 nAChR subunits are expressed in the MHb (Shih et al., 2014).
However, no statistically significant, sufficiently powered main effects were
found for the MHb in this sample.
The Interpeduncular Nucleus (IPN) and Raphe Nucleus (RN)were selected for
analysis; both of these regions are involved in directing and maintaining sleep-wake
cycles. The clinical literature indicates that sleep problems are common, especially early
in life, for offspring exposed to maternal tobacco (Blood-Siegried et al., 2010); Boychuck
et al., (2011) found that newborns experience withdrawals following parturition, and
nicotine withdrawal during the early days of birth, shifts sleep-wake patterns, potentially
making offspring more vulnerable to cardiac complications.
No significant, sufficiently powered differences were found for any receptor
subtype in either the IPN or the RN.

7.5.4 Cortices: Insular (Agranular) Cortex, Auditory Cortex, Motor Cortex,
Parietal Cortex, Somatosensory Cortex

The Insular Cortex was selected for densitometry because of this region’s
involvement in smoking behavior. The insular cortex is important for tobacco addiction
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in human smokers, and it’s ablation can dramatically decrease, and even eliminate
smoking behaviors (Hollander et al., 2008). In the Insular Cortex, receptor density was
altered as a function of Treatment; the PN group had greater levels of α7 nAChR
expression density, and both α4β2 and α7 levels were significantly different between
neonatal and adolescent groups; adolescents expressed greater density for both types of
nAChR.
The Auditory Cortex function is appreciably damaged by nicotine perinatal
nicotine exposure (Armamakis et al., 2000). Moreover, the Auditory Cortex is part of the
circuitry involved in attention and sensory processing (along with the Parietal and
Somatosensory Cortices), and nicotine exposure during prenatal and perinatal periods
underlies several attention and sensory processing cognitive deficits among offspring
(Heath & Piccioto, 2008).
Densitometry results in the Auditory Cortex were mixed, but nAChR expression
was changed for both α4β2 and α7 nAChRs; PN animals had lower levels of α4β2
nAChRs compared to PS animals, but the opposite was found for density of α7 nAChR
expression; PN animals had significantly higher levels of nAChR expression.
The Motor Cortex was included as a control region; as expected, the only
significant difference for this region was a function of Age, with adolescents expressing
higher nAChR levels. The Parietal Cortex densitometry revealed fewer α4β2 nAChRs
expressed in the PN group. In the Somatosensory Cortex, nAChR expression varied as a
function of Treatment and Age, with a significant interaction revealed.
PN animals expressed fewer α4β2 nAChRs, but adolescents expressed higher
levels of α4β2 nAChRs. The graphic in this report shows that PN animals, as neonates,
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have significantly higher α4β2 levels, but by adolescence, both PN and PS groups appear
to approach similar means.

7.6 SUMMARY
The results of this study indicate low-dose IV prenatal nicotine has complex
effects on nAChR expression levels in the neonatal and adolescent rat brain. The
upregulation of nAChRs in brain regions underlying motivated behavior, point to a
potential mechanism for the long-term changes in motivated, drug-seeking behavior seen
in the population of maternal-tobacco smoke exposed offspring.
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